WO2003089624A2 - Fc receptor homolog, reagents, and uses thereof - Google Patents

Fc receptor homolog, reagents, and uses thereof Download PDF

Info

Publication number
WO2003089624A2
WO2003089624A2 PCT/US2003/009600 US0309600W WO03089624A2 WO 2003089624 A2 WO2003089624 A2 WO 2003089624A2 US 0309600 W US0309600 W US 0309600W WO 03089624 A2 WO03089624 A2 WO 03089624A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
fcrh
nucleic acid
amino acid
antibody
Prior art date
Application number
PCT/US2003/009600
Other languages
French (fr)
Other versions
WO2003089624A3 (en
Inventor
Randall S. Davis
Max D. Cooper
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Priority to AU2003245239A priority Critical patent/AU2003245239A1/en
Priority to CA002480404A priority patent/CA2480404A1/en
Priority to EP03738876A priority patent/EP1490085A2/en
Priority to US10/508,374 priority patent/US7317087B2/en
Priority to JP2003586337A priority patent/JP2005521429A/en
Publication of WO2003089624A2 publication Critical patent/WO2003089624A2/en
Publication of WO2003089624A3 publication Critical patent/WO2003089624A3/en
Priority to US11/835,226 priority patent/US8648171B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This invention relates generally to immunology and modulation of immunologic responses in the context of inflammatory diseases and cancer.
  • Receptors for the Fc region (FcRs) of Igs have broad tissue distribution patterns and can modulate cellular and humoral immunity by linking their antibody ligands with effector cells of the immune system (Ravetch, J. V. & Kinet, J.-P. (1991) Aimu. Rev. Immunol. 9, 457-492; Daeron, M. (1997) Annu. Rev. Immunol. 15, 203-234.
  • These cellular receptors have the ability to sense humoral concentrations of antibody, initiate cellular responses in host defense, and participate in autoimmune disorders (Ravetch, J. V. & Bolland, S. (2001) Annu. Rev. Immunol. 19, 275-290).
  • Ig isotype specificity and cellular distribution of the individual FcR.
  • Ig superfamily members share similarities in their ligand binding subunits, and they may have inhibitory or activating signaling motifs in their intracellular domains or instead pair with signal transducing subunits possessing activating signaling motifs.
  • This multigene family which includes the Fc ⁇ R (Kremer, E. J. et al. (1992) Hum. Genet. 89, 107-108) and the natural killer cell Ig-like receptors (Wagtmann, N. et al. (1997) Curr. Biol. 7, 615-618), is located in a human chromosome 19ql3 region known as the leucocyte receptor complex (LRC) (Wende, H. et al. (1999) Mamm. Genome 10, 154-160; Wilson, M. J. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 4778-4783).
  • LRC leucocyte receptor complex
  • Ig-like multigene families belong to a larger class of receptors characterized by their possession of common cytoplasmic tyrosine-based signaling motifs.
  • These can be either immunoreceptor tyrosine-based activation motifs (ITAMs) containing two repeats of the consensus sequence Y-X-X-L/I spaced by 6-8 amino acids (E/D)-X-X-Y-X-X-(L/I)-X 6 - 8 -Y-X-X-(L/I) (SEQ ID NO:64, with six amino acid between the consensus sequences; SEQ ID NO:65, with seven amino acid residues between the consensus sequences; and SEQ ID NO:66, with eight amino acid residues between the consensus sequences) or immunoreceptor tyrosine-based inhibitory motifs (IT s) with a 6-amino acid consensus sequence (I/V/L/S)-X-Y-X-X-(L/V) (SEQ ID NO:67) (Reth
  • IT AM tyrosines are rapidly phosphorylated by Src family kinases to initiate a cascade of signaling events that trigger cellular activation.
  • the tyrosines provide a docking site for phosphatases containing Src homology 2 domains that can abrogate cellular activation (Long, E. O. (1999) Annu. Rev. Immunol. 17, 875-904; Unkeless, J. C. & Jin, J. (1997) Curr. Opin. Immunol. 9, 338-343).
  • the balance in the utilization of these activating and inhibitory receptor pairs can serve to modulate cellular responses to a variety of stimuli.
  • the genes encoding the classical Fc ⁇ Rs, Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ Rm, and Fc ⁇ RI lie on the long arm of chromosome 1 (lq21-23) near the polymeric Ig receptor (plgR) and Fc ⁇ / ⁇ R genes (lq32) (20-23).
  • Members of this FcR subfamily have relatively low extracellular homology with the FcR-related genes that reside in the LRC on chromosome 19.
  • the ligand binding chain of the Fc ⁇ R coassociates with the ITAM containing FcR common ⁇ -chain (Pfefferkorn, L. C. & Yeaman, G. R. (1994) J. Immunol. 153, 3228-3236; Morton, E.
  • this invention in one aspect, relates to members of a cluster of FcR and FcR gene relatives encoded, for example, by genes in the human chromosome lq21-23 region, or analogous region in non-human subjects.
  • the members are Type I transmembrane receptors, or alternatively spliced forms thereof, with homology to the FcR family and are referred to herein as FcRHs.
  • Each FcRH can comprise an extracellular region, a transmembrane region, and a cytoplasmic region.
  • the cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ("ITIMs" or "ITAMs).
  • ITIMs immunoreceptor tyrosine-based inhibitory or activation motifs
  • the invention relates to polypeptides corresponding to isolated FcRHs (e.g., huFcRH 1, 2, 3, and 6 and moFcRHl, 2, and 3), as well as fragments and isoforms thereof.
  • the invention further relates to nucleic acids that encode the FcRHs, as well as hybridization probes related thereto and complementary sequences.
  • the invention further provides vectors and cells related to the nucleic acids of the invention.
  • the invention further relates to making an FcRH, or a fragment or variant thereof, comprising culturing a cell comprising a vector of the invention under conditions permitting expression of the FcRH.
  • the invention also provides an antibody reagent kit comprising the antibody, or a fragment or variant thereof, and reagents for detecting binding of the antibody, fragment, or antibody variant to a ligand.
  • the invention further relates to uses of the polypeptides, nucleic acids and antibodies of the invention. For example, the invention relates to methods of diagnosing and methods of treating a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject. The invention also relates to modulation of a humoral immune response in a subject.
  • Figure 1 shows the relative position of the FcRH locus within the FcR cluster on chromosome 1.
  • the cytogenetic location of the FcR genes is approximated from the GenBank Mapview database.
  • the BAC clones (4, GenBank accession no. AL139409; 3, GenBank accession no. AL356276; 2, GenBank accession no. AL135929; and 1, GenBank accession no. AL353721) that span the locus are oriented in relation to their respective FcRH genes (shaded area).
  • Figure 2 shows the structural and sequence diversity of FcRHl, FcRH2, and
  • FIG. 1 is a schematic representation of FcRH molecules.
  • the three cDNAs encode type I transmembrane proteins with similar extracellular domains, but different cytoplasmic regions.
  • the extracellular (EC) regions contain different numbers of C2- like Ig domains and potential sites of N-linked glycosylation.
  • the transmembrane (TM) domains are uncharged, except in the case of FcRH 1.
  • the cytoplasmic (CY) region of FcRHl contains two ITAMs (light gray boxes) and one ITAM-like region (small, lined box), whereas FcRH2 contains one ITAM and two ITIMs (dark gray boxes).
  • FcRH3 has a long cytoplasmic tail with one ITAM, one ITIM, and an ITAM-like region.
  • the amino acid length of each region is indicated.
  • Figure 2B shows the multiple alignment comparison of FcRHl, FcRH2, and FcRH3 amino acid sequences (one-letter code) based on the FcRH3 sequence.
  • Amino acid identity is represented by dots, and gaps are indicated by dashes. Predicted N-linked glycosylation sites and transmembrane domains are underlined in black. Consensus ITAM (bold) and ITIM (bold, underlined) motifs are indicated. Putative structural domains are labeled: SP, signal peptide; EC, extracellular domain; MP-TM, membrane proximal-transmembrane; and CY, cytoplasmic regions. Amino acid lengths are indicated in parentheses.
  • Figure 3 shows a composite analysis of the extracellular homology among FcRH and FcR family members. Pairwise analysis of individual Ig-like subunits was performed with the CLUSTAL method algorithm using FcRH3 as the index of comparison. Individual homologous domains are coded to indicate relatedness. Percent amino acid identities for related domains are indicated and aligned in relation to the comparative FcRH3 subunit. The amino acid identity for the membrane proximal domains (light gray subunits) of FcRH5 are provided as the range of identity for all individually related domains. Comparisons that are not applicable are left blank. Amino acid sequences were derived from IRTA1 (GenBank accession no. AF343659), IRTA2 (GenBank accession no.
  • Figure 4 shows the relative location of the mouse FcR family. Location is indicated in reference to the human FcR related genes at Ch lq21-23 and their orthologous loci on mouse Ch 3 and Ch 1.
  • the microsatellite marker d3Mitl87 is located within moFcRH 1.
  • Figure 5 shows the multiple alignment comparisons of huFcRHl-5 and mouse FcRHl and 2 amino acid sequences (one-letter code) based on the FcRH3 sequence. Amino acid gaps are indicated by dashes. Consensus ITAM (underlined) and ITIM (italic, underlined) motifs are indicated. Amino acid lengths are indicated in parentheses.
  • Figure 6 shows domains marked to indicate relatedness of the Ig-like subunits.
  • Ig-like domain homology was determined by generation of a phylogenetic tree using DNAStar software with the CLUSTAL program and assigning arbitrary colors to individual Ig-domains of a given branch.
  • Amino acid identities for full length, extracellular and, cytoplasmic domain comparisons are based on huFcRH3. Closest cytoplasmic relatives are indicated in parentheses. Most identical extracellular comparisons between mouse and human relatives are highlighted in horizontal lines. Comparisons that are not applicable are left blank.
  • Figure 7 shows the domains of huFcRHl-6, moFcRHl-3 and related proteins. Domains are colored to indicate relatedness of the Ig-like subunits. Ig-like domain homology was determined by generation of a phylogenetic tree using DNAStar software with the CLUSTAL program and assigning arbitrary colors to individual Ig-domains of a given branch. Amino acid identities for full length, extracellular and, cytoplasmic domain comparisons are based on huFcRH3. Closest cytoplasmic relatives are indicated in parentheses. Most identical extracellular comparisons between mouse and human relatives are highlighted in red. Comparisons that are not applicable are left blank.
  • Figure 8 shows the structural characteristics of the mouse FcRH isoforms.
  • Ranges may be expressed herein as from “about” one particular value, and/or to
  • subject is meant an individual.
  • the subject is a mammal such as a primate, and, more preferably, a human.
  • the term “subject” can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.).
  • isolated nucleic acid is meant a nucleic acid the structure of which is not identical to that of the naturally occurring nucleic acid or to that of any fragment of the naturally occurring genomic nucleic acid spanning more than three separate genes.
  • the term therefore covers, for example, (a) a DNA which has the sequence of part of the naturally occurring genomic DNA molecules but is not flanked by both of the coding sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as cDNA, a genomic fragment, a fragment produced by polymerase chain reaction, or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a
  • label is meant any detectable tag that can be attached directly (e.g., a fluorescent molecule integrated into a polypeptide or nucleic acid) or indirectly (e.g., by way of binging to a primary antibody a secondary antibody with an integrated fluorscent molecule) to the molecule of interest.
  • a “label” is any tag that can be visualized with imaging methods.
  • the detectable tag can be a radio-opaque substance, radiolabel, a fluorescent label, or a magnetic label.
  • the detectable tag can be selected from the group consisting of gamma-emitters, beta-emitters, and alpha-emitters, gamma- emitters, positron-emitters, X-ray-emitters and fluorescence-emitters suitable for localization.
  • Suitable fluorescent compounds include fluorescein sodium, fluorescein isothiocyanate, phycoerythrin, and Texas Red sulfonyl chloride. See, de Belder & Wik (Preparation and properties of fluorescein-labelled hyaluronate. Carbohydr.
  • the invention provides members of a cluster of FcR and FcR gene relatives encoded by genes in the human chromosome lq21-23 region, or analogous region in non-human subjects, including for example, chromosome 3 in mouse.
  • a consensus amino acid motif based on the Fc ⁇ RI, Fc ⁇ RU, Fc ⁇ RUI, and plgR extracellular regions, was used in a GenBank protein database query to identify member of the gene subfamily. Genomic clones were identified that were found to contain FcR relatives and are termed the Fc receptor homolog (FcRH) subfamily: specifically, FcRHl,
  • FcRH2, FcRPD, and FcRH6 are mouse Fc receptor homologs designated moFcRl , 2, and 3.
  • homology is meant about 25% percent homology or greater. Homology is also characterized by proximity in the location of the genes and by similarities as identified in a composite analysis. As used herein, “percent homology" of two amino acid sequences or of two nucleic acid sequences is determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990)). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410 (1990)).
  • Gapped Blast is utilized as described in Altschul et al. (Nucl. Acids Res. 25: 3389-3402 (1997)).
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • FcRH is meant a Type I transmembrane receptor, or an alternatively spliced form thereof, including, for example, a secreted form or a GPI-anchored form, with homology to the classical Fc receptor family.
  • the FcRH shows homology with the extracellular regions of Fc ⁇ RI, Fc ⁇ RII, Fc ⁇ RIII, or plgR. More specifically, the FcRH shows homology with an amino acid sequence corresponding with the amino terminal sequences of the second Ig domains of the Fc ⁇ Rs and the third Ig domain of plgR or Fc ⁇ RHl.
  • the FcRH can comprise an extracellular region, a transmembrane region, and a cytoplasmic region.
  • the extracellular region preferably comprises one or more Ig domains, and more preferably less than 9, and even more preferably less than 7 or less than 8 Ig domains.
  • the cytoplasmic region comprises more than 107 (including more than 108, 109, 110, 111, 112, 113, 114, 115, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, or 145 amino acids).
  • the cytoplasmic region comprises less than 104 amino acids (including less than 103, 102, 101, 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80).
  • the cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ("ITIMs" or "ITAMs).
  • ITAMs immunoreceptor tyrosine-based inhibitory or activation motifs
  • the invention provides isolated FcRHs (e.g., huFcRH 1, 2, 3, and 6, and moFcRHl-3, as described in detail below), as well as fragments and isoforms thereof.
  • the isolated amino acid sequences provided herein optionally are combined with a human signal sequence (e.g., MLPRLLLLICAPLCEP (SEQ ID NO:29), MLLWSLLVIFDAVTEQADS (SEQ ID NO:30), MLLWLLLLILTPGREQS (SEQ ID NO:31), MLLWTAVLLFVPCVG (SEQ ID NO:32)) or a mouse signal sequence (e.g., MPLCLLLLVFAPVGVQS (SEQ ID NO:69), MLPWLLLLICALPCEPA (SEQ ID NO:72), MSGSFSPCVVFTQMWLTLLWTPVN (SEQ ID NO:79)).
  • a human signal sequence e.g., MLPRLLLLICAPLCEP (SEQ ID NO:29), MLLWSLLVIFDAVTEQADS (SEQ ID NO:30), MLLWLLLLILTPGREQS (SEQ ID NO:31), MLLWTAVLLFVPCVG (SEQ ID NO:32)
  • the invention provides huFcRHl and its fragments and isoforms.
  • the extracellular region comprises less than four Ig domains.
  • the cytoplasmic region comprises less than 104 amino acids and, even more preferably, comprises less than 104 and more than 86 amino acids.
  • the transmembrane region comprises an acidic amino acid (e.g., glutamate or aspartate).
  • the isolated FcRH of the invention comprises a cytoplasmic region having the amino acid sequence of SEQ ID NO:l, in the presence or absence of conservative amino acid substitutions.
  • the isolated FcRH wherein the extracellular region comprises the amino acid sequence of SEQ ID NO:21, in the presence or absence of conservative amino acid substitutions, and in the presence and absence of a signal sequence. More specifically, the isolated FcRH comprises the amino acid sequence of SEQ ID NO:2, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence.
  • the signal sequence is MLPRLLLLICAPLCEP (SEQ ID NO: 29).
  • the FcRH of the invention is expressed by myeloid cells (e.g., granulocytes and monocytes).
  • Additional characteristics of the full length FcRHl include a predicted molecular weight of about 46-47 kDaltons; about 425-435 (e.g., 429) amino acids in length with about 35 strongly basic(+) amino acids (K,R), about 45 strongly acidic(-) amino acids (D,E), about 144 hydrophobic amino acids (A,I,L,F,WN), and aboutl27 polar amino acids ( ⁇ ,C,Q,S,T,Y); a predicted isolelectric point of about 5-5.5 (e.g., 5.310); and charge of about -9 at PH 7.0.
  • the invention provides an isolated FcRH corresponding to huFcRH2, its fragments, or isoforms.
  • the invention provides a FcRH wherein the cytoplasmic region comprises less than 99 amino acids (e.g., 80, 81, 82, 83, 84, 85,
  • the isolated FcRH has a cytoplasmic region that comprises the amino acid sequence of SEQ ID NO:3, in the presence or absence of conservative amino acid substitutions, or an extracellular region comprising SEQ TD
  • the isolated FcRH comprises the amino acid sequence of SEQ ID NO:4, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence, h one embodiment, the signal sequence WSLLVTFDANTEQADS (SEQ ID NO: 30).
  • FcRHl Additional characteristics include a predicted molecular weight of about 50-60 kDaltons; about 495-515 (e.g., 508) amino acids in length with about 44 strongly basic(+) amino acids (K,R), about 49 strongly acidic(-) amino acids (D,E), about 175 hydrophobic amino acids (A,I,L,F,W,V), and about 161 polar amino acids (N,C,Q,S,TN); a predicted isolelectric point of about 6-6.5 (e.g., 6.188); and charge of about -4 atPH 7.0.
  • the invention provides huFcRH3, its fragments, and isoforms.
  • the invention provides an isolated FcRH having a cytoplasmic region that comprises more than 107 amino acids (e.g., 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 212, 122, 123, 124, 125, 126 ,127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 247, 148, 149, 150 amino acids).
  • the isolated FcRH has a cytoplasmic region comprising one ITAM and one ITIM.
  • the cytoplasmic region comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23, in the presence or absence of conservative amino acid substitutions.
  • the extracellular domain of the FcRH comprises the amino acid sequence of SEQ ID NO:24, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence.
  • an isolated FcRH comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:25, in the presence or absence of one or more amino acid substitutions, and in the presence or absence of a signal sequence.
  • the signal sequence comprises
  • FcRHl MLLWLLLLILTPGREQS (SEQ ID NO:31). Additional characteristics of the full length FcRHl include a predicted molecular weight of about 80-90 kDaltons; about
  • 725-740 amino acids in length with about 68 strongly basic(+) amino acids (K,R), about 75 strongly acidic(-) amino acids (D,E), about 232 hydrophobic amino acids (A,I,L,F,WN), and about 224 polar amino acids ( ⁇ ,C,Q,S,TN); a predicted isolelectric point of about 6.5-7.0 (e.g., 6.852); and charge of about -2 atPH 7.0.
  • the invention further provides an isolated huFcRH ⁇ , its fragments, and isoforms. More specifically, the FcRH comprises a cytoplasmic region having the amino acid sequence of SEQ ID NO:26, in the presence or absence or one or more conservative amino acid substitutions.
  • the extracellular domain comprises the amino acid sequence of SEQ ID NO:27, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence.
  • the invention further provides a polypeptide comprising the amino acid sequence of SEQ ID NO:l, 21, 2, 3, 22, 4, 5, 23, 24, 6, 25, 26, 27, or 28, in the presence or absence of conservative amino acid substitutions.
  • the invention also provides a polypeptide having at least 80, 85, 90, or 95% homology with SEQ ID NOs: 1, 21, 2, 3, 22, 4, 5, 23, 24, 6, 25, 26, 27, or 28.
  • the invention further provides an isolated moFcRHl isoform, its fragments, and isoforms.
  • the moFcRHl is an isoform of SEQ ID NO:68. More specifically, the FcRH comprises four Ig domains, optionally having the sequence of SEQ ID NO: 70, in the presence or absence or one or more conservative amino acid substitutions, and in the presence or absence of a signal sequence (e.g., the sequence of SEQ ID NO:71).
  • the invention further provides an isolated moFcRH2, its fragments, and isoforms.
  • the provided isoforms include one isoform with a transmembrane region and one isoform lacking the transmembrane region.
  • the FcRH comprises a cytoplasmic region having the amino acid sequence of SEQ ID NO:76, in the presence or absence or one or more conservative amino acid substitutions.
  • the extracellular domain comprises the amino acid sequence of SEQ ID NO:74, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence.
  • FcRH having the amino acid sequence of SEQ ID NO:73, which comprises a transmembrane region, or SEQ ID NO: 77, which lacks the transmembrane region, hi each case, the FcRH sequence can include the presence or absence of conservative amino acid substitutions, and the presence or absence of a signal sequence, h one embodiment the signal sequence is the sequence of SEQ ED NO:72.
  • the invention also provided a moFcRH3, its fragments and isoforms.
  • the cytoplasmic region can comprise the amino acid sequence of SEQ DD NO:81, in the presence or absence of conservative amino acid substitutions.
  • the extracellular domain comprises the amino acid sequence of SEQ ID NO: 80, in the presence or absence of conservative amino acid substitutions or in the presence or absence of a signal sequence (e.g., the sequence of SEQ ID NO:79).
  • the full length sequence optionally has the amin oacid sequence of SEQ ID NO:78, in the presence or absence of conservative amino acid substitutions or in the presence or absence of a signal sequence (e.g., the sequence of SEQ ID NO:79).
  • Fragments, variants, or isoforms of the FcRHs of the invention are provided. It is understood that these terms include functional variants. Fragments can include the cytoplasmic region, the extracellular region, the transmembrane region or any portion of at least 10 amino acids or any combination of the regions or portions.
  • the variants are produced by making amino acid substitutions, deletions, and insertions, as well as post- translational modifications. Variations in post-translational modifications can include variations in the type or amount of carbohydrate moieties of the protein core or any fragment or derivative thereof.
  • Variations in amino acid sequence may arise naturally as allelic variations (e.g., due to genetic polymo ⁇ hism) or may be produced by human intervention (e.g., by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants. These modifications can result in changes in the amino acid sequence, provide silent mutations, modify a restriction site, or provide other specific mutations. Amino acid sequence modifications fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl termi al fusions as well as intrasequence insertions of single or multiple amino acid residues.
  • Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues.
  • Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about 2 to 6 residues are deleted at any one site within the protein molecule.
  • These variants ordinarily are prepared by site-specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known and include, for example, Ml 3 primer mutagenesis and PCR mutagenesis.
  • Amino acid substitutions are typically of single residues but may include multiple substitutions at different positions; insertions usually will be on the order of about from 1 to 10 amino acid residues but can be more; and deletions will range about from 1 to 30 residues, but can be more. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with Table 1 and are referred to as conservative substitutions.
  • substitutions that are less conservative than those in Table 1 are made by selecting substitutions that are less conservative than those in Table 1, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain.
  • substitutions that in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g.
  • leucyl isoleucyl, phenylalanyl, valyl or alanyl
  • a cysteme or proline is substituted for (or by) any other residue
  • a residue having an electropositive side chain e.g., lysyl, arginyl, or histidyl
  • an electronegative residue e.g., glutamyl or aspartyl
  • a residue having a bulky side chain e.g., phenylalanine
  • one not having a side chain e.g., glycine
  • Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Tlir/Ser) or O-glycosylation (Ser or Thr).
  • Deletions of cysteme or other labile residues also may be desirable.
  • Deletions or substitutions of potential proteolysis sites, e.g. Arg is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.
  • Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecular Properties, W. H.
  • nucleic acid that encodes the FcRH of the invention.
  • the nucleic acid can be single or double stranded and can be RNA or DNA.
  • the invention provides an isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ID NO:l, SEQ ID NO:21, SEQ ID NO:2.
  • SEQ ID NO: 3 SEQ ID NO:22, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:6, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:77, SEQ DD NO:78, SEQ ID NO:80, SEQ ID NO:81, optionally with conservative amino acid substitutions.
  • the nucleic acid further encodes a signal sequence (e.g., the signal sequences of SEQ ED NO:29, 30, 31, 32, 71, 75, 79).
  • the isolated nucleic acid optionally encodes the sequences with 80, 85, 90, or 95 % identity.
  • the invention provides an isolated nucleic acid, comprising a nucleotide sequence of SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:8, SEQ ID NO:34, SEQ ID NO:9, SEQ ID NO: 14, SEQ DD NO: 10, SEQ DD NO:36, SEQ ID NO:ll, SEQ ID NO:15, SEQ ID NO: 16, SEQ ID NO:12, SEQ ID NO:38, SEQ ED NO:17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20; SEQ ID NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ DD NO:87, SEQ ID NO:88, SEQ DD NO:89, SEQ DD NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ED NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99
  • the isolated nucleic acid can further included bases that encode a signal sequence and thus the nucleotide sequence encoding the extracellular region or full-length huFcRHl, 2, 3, or 6 can optionally further comprise the nucleotide sequence of SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO: 39.
  • the isolated nucleic acids for moFcRHs include nucleic acid sequences that encode signal sequences as well, including for example, those portions of nucleic acid sequences SEQ ID NO: 101, SEQ ID NO:97, SEQ ID NO:94, SEQ ID NO:91, SEQ ID NO:88, SEQ ID NO:84.
  • the nucleic acid that encodes the full length FcRHl includes about 1290 bases.
  • the nucleic acid that encodes the full length FcRH2 includes about 1527 bases, and the nucleic acid that encodes the full length FcRH3 includes about 2205 bases.
  • the invention also provides an isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO:7, SEQ ED NO:13, SEQ ID NO:8, SEQ ED NO:34, SEQ ID NO:9, SEQ ED NO:14, SEQ ED NO:10, SEQ ID NO:36, SEQ ED NO:l 1, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:12, SEQ ID NO:38, SEQ IDNO:17, SEQ ID NO:18, SEQ IDNO:19, and SEQ IDNO:20; SEQ DD NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95
  • nucleic acid that hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ ED NO:7, SEQ ED NO: 13, SEQ ID NO:8, SEQ ID NO:34, SEQ ID NO:9, SEQ ID NO: 14, SEQ ID NO:10, SEQ ID NO:36, SEQ EDNO:ll, SEQ ED NO:15, SEQ ID NO:16, SEQ EDNO:12, SEQ ED NO:38, SEQ ID NO:17, SEQ DD NO: 18, SEQ ID NO:19, and SEQ ED NO:20; SEQ ID NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ED NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97
  • hybridizing under stringent conditions or “hybridizing under highly stringent conditions” is meant that the hybridizing portion of the hybridizing nucleic acid, typically comprising at least 15 (e.g., 20, 25, 30, or 50 nucleotides), hybridizes to all or a portion of the provided nucleotide sequence under stringent conditions.
  • hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions.
  • sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide.
  • the hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.
  • the hybridizing portion of the hybridizing nucleic acid is at least 80%, for example, at least 90%, 95%, or 98%, identical to the sequence of or a portion of a nucleic acid encoding an FcRH of the invention, or its complement.
  • Hybridizing nucleic acids of the invention can be used, for example, as a cloning probe, a primer (e.g., for PCR), a diagnostic probe, or an antisense probe.
  • Hybridization of the oligonucleotide probe to a nucleic acid sample typically is performed under stringent conditions. Nucleic acid duplex or hybrid stability is expressed as the melting temperature or Tm, which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions.
  • sequences are to be identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., SSC or SSPE). Assuming that a 1% mismatch results in a 1°C decrease in the Tm, the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequence having >95% identity with the probe are sought, the final wash temperature is decreased by 5 °C). In practice, the change in Tm can be between 0.5 °C and 1.5 °C per 1% mismatch.
  • salt e.g., SSC or SSPE
  • Stringent conditions involve hybridizing at 68 °C in 5x SSC/5x Denhardt's solution 1.0% SDS, and washing in 0.2x SSC/0.1% SDS at room temperature.
  • Moderately stringent conditions include washing in 3x SSC at 42 °C.
  • the parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, NY) at Unit 2.10.
  • nucleic acids of the present invention are optionally labeled, directly or indirectly.
  • labeled nucleic acids are useful in various diagnostic techniques including for example, in situ hybridization, FISH, in situ PCR, and PRTNS. Both methods involve the preparation of short sequences of sing ⁇ e-stranded nucleic acid probes that are complementary to the nucleic acid sequences that encode an FcRH.
  • an expression vector comprising a nucleic acid of the invention, wherein the nucleic acid is operably linked to an expression control sequence.
  • Such an expression vector can be designed to be expressed by eukaryotic cells or prokaryotic cells.
  • the vectors of the present invention thus provide DNA molecules which are capable of integration into a prokaryotic or eukaryotic chromosome and expression.
  • the inserted genes in viral and retroviral vectors usually contain promoters, and/or enhancers to help control the expression of the desired gene product.
  • a promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site.
  • a promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements. It has been shown that all specific regulatory elements can be cloned and used to construct expression vectors that are selectively expressed in specific cell types.
  • GFAP glial fibrillary acetic protein
  • expression vectors used in eukaryotic host cells may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contain a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA.
  • polyadenylation signals in expression constructs are well established. It is preferred that homologous polyadenylation signals be used in the transgene constracts. In certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.
  • the invention further provides transfer vectors, which include any nucleotide construction used to deliver genes into cells (e.g., a plasmid), or as part of a general strategy to deliver genes, e.g., as part of recombinant retrovirus or adenoviras (Ram et al. Cancer Res. 53:83-88, (1993)).
  • plasmid or viral vectors are agents that transport the disclosed nucleic acids into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered.
  • the FcRHs are derived from either a virus or a retrovirus.
  • Viral vectors include, for example, Adenoviras, Adeno-associated virus, He ⁇ es virus, Vaccinia virus, Polio virus, ADDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone. Also preferred are any viral families that share the properties of these viruses that make them suitable for use as vectors. Retroviruses include Murine Maloney Leukemia virus, MMLV, and retrovirases that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors, and for this reason are a commonly used vector.
  • Adenoviras vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non- dividing cells.
  • Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature.
  • a preferred embodiment is a viral vector which has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens.
  • Viral vectors can have higher transaction (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells.
  • viral vectors contain, nonstractural early genes, stractural late genes, an RNA polymerase HI transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the transcription and replication of the viral genome.
  • viruses When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promotor cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material.
  • the necessary functions of the removed early genes are typically supplied by cell lines that have been engineered to express the gene products of the early genes in trans.
  • a retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms.
  • Retroviral vectors in general, are described by Verma, I.M., Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is inco ⁇ orated by reference herein. Examples of methods for using retroviral vectors for gene therapy are described in U.S. Patent Nos.
  • a retrovirus is essentially a package which has packed into it nucleic acid cargo.
  • the nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat.
  • a packaging signal In addition to the package signal, there are a number of molecules that are needed in cis, for the replication, and packaging of the replicated virus.
  • a retroviral genome contains the gag, pol, and env genes which are involved in the making of the protein coat.
  • Retrovirus vectors typically contain a packaging signal for inco ⁇ oration into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome.
  • gag, pol, and env genes allow for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert. Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line.
  • a packaging cell line is a cell line that has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal.
  • the vector carrying the DNA of choice When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.
  • viruses as vectors are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles.
  • Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, J. Clin. Invest. 92:1580-1586 (1993); Kirshenbaum, J. Clin. Invest. 92:381-387 (1993);
  • Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenoviras (Chardonnet and Dales, Virology 40:462-477 (1970); Brown and Burlingham, J. Virology 12:386-396 (1973); Svensson and Persson, J. Virology 55:442-449 (1985); Seth, et al., J. Virol. 51:650-655 (1984); Seth, et al., Mol. Cell. Biol. 4:1528-1533 (1984); Varga et al., J. Virology 65:6061-6070 (1991); Wickham et al., Cell 73:309-319 (1993)).
  • a viral vector can be one based on an adenoviras which has had the El gene removed and these virons are generated in a cell line such as the human 293 cell line, hi another preferred embodiment both the El and E3 genes are removed from the adenoviras genome.
  • AAV adeno-associated virus
  • This defective parvoviras is a preferred vector because it can infect many cell types and is nonpathogenic to humans.
  • AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred.
  • An especially preferred embodiment of this type of vector is the P4.1 C vector produced by Avigen, San Francisco, CA, which can contain the he ⁇ es simplex virus thymidine kinase gene, HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.
  • the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene.
  • ITRs inverted terminal repeats
  • Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvoviras.
  • AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector.
  • the AAV ITRs, or modifications thereof, confer infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression.
  • United States Patent No. 6,261,834 is herein inco ⁇ roated by reference for material related to the AAV vector.
  • these vectors can be used for transfection, where large amounts of protein can be generated transiently in vitro.
  • He ⁇ esviras amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes.
  • Other useful systems include, for example, replicating and host-restricted non-replicating vaccinia viras vectors.
  • the invention also provides an isolated cell comprising a vector of the invention.
  • the isolated cell can be either a eukaryotic or prokaryotic cell, such as strains of E. coli, Pseudomonas, Bacillus , Streptomyces; fungi such as yeasts (Saccharomyces , and methylotrophic yeast such as Pichia, Candida, Hansenula, and Torulopsis); and animal cells, such as CHO, Rl.l, B-W and LM cells, African Green Monkey kidney cells (for example, COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (for example, Sf9), and human cells and plant cells in tissue culture.
  • a eukaryotic or prokaryotic cell such as strains of E. coli, Pseudomonas, Bacillus , Streptomyces; fungi such as yeasts (Saccharomyces , and methylotrophic yeast such as Pichia,
  • Also provided is a method of making a FcRH, or a fragment or variant thereof comprising culturing a cell comprising a vector of the invention under conditions permitting expression of the FcRH.
  • the method comprises culturing a cell comprising an exogeneous nucleic acid that encodes the FcRH, fragment, or variant, wherein the exogeneous nucleic acid is operably linked to an expression control sequence, and wherein the culture conditions permit expression of the FcRH, fragment, or variant under the control of the expression control sequence; harvesting the medium from the cultured cells, and isolating the FcRH, fragment, or varinat from the cell or culture medium.
  • the exogenous nucleic acid is the nucleotide sequence of SEQ ED NO:7, SEQ ID NO: 13, SEQ ED NO:8, SEQ ID NO:34, SEQ ID NO:9, SEQ ID NO: 14, SEQ ID NO:10, SEQ ID NO:36, SEQ ID NO:ll, SEQ ED NO:15, SEQ ID NO:16, SEQ ID NO:12, SEQ ID NO:38, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ
  • the exogenous nucleic acid further comprises a nucleotide sequence that encodes a signal sequence.
  • the cell can be any known host cell, including for example, a prokaryotic or eukaryotic cell.
  • the nucleic acids that are delivered to cells typically contain expression controlling systems.
  • the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product.
  • FcRH may be produced using prokaryotic host cells (e.g., Escherichia coli) or eukaryotic host cells (e.g., Saccharomyces cerevisiae, insect cells such as Sf9 cells, or mammalian cells such as CHO cells, COS-1, NTH 3T3, or HeLa cells). These cells are commercially available from, for example, the American Type Culture Collection, RockviUe, MD (see also F.
  • prokaryotic host cells e.g., Escherichia coli
  • eukaryotic host cells e.g., Saccharomyces cerevisiae, insect cells such as Sf9 cells, or mammalian cells such as CHO cells, COS-1, NTH 3T3, or HeLa cells.
  • a nucleic acid sequence encoding an FcRH is introduced into a plasmid or other vector, which is then used to transform living cells. Constracts in which a cDNA containing the entire FcRH coding sequence, a fragment of the FcRH coding sequence, amino acid variations of the FcRH coding sequence, or fusion proteins of the aforementioned, inserted in the correct orientation into an expression plasmid, may be used for protein expression. In some cases, for example, it may be desirable to express the FcRH coding sequence under the control of an inducible or tissue-specific promoter. Eukaryotic expression systems permit appropriate post-translational modifications to expressed proteins.
  • eukaryotic, and more preferably mammalian expression systems allow glycosylations patterns comparable to naturally expressed FcRH.
  • Transient transfection of a eukaryotic expression plasmid allows the transient production of FcRH by a transfected host cell.
  • FcRH may also be produced by a stably- transfected mammalian cell line.
  • a number of vectors suitable for stable transfection of mammalian cells are available to the public (e.g., see Pouwels et al., Cloning Vectors: A Laboratory Manual, 1985, Supp. 1987), as are methods for constructing such cell lines (see e.g., F.
  • eukaryotic expression system is the baculovirus system using, for example, the vector pBacPAK9, which is available from Clontech (Palo Alto, CA). If desired, this system may be used in conjunction with other protein expression techniques, for example, the myc tag approach described by Evan et al. (Mol. Cell Biol. 5:3610-3616, 1985) or analogous tagging approaches, e.g., using a hemagluttinin (HA) tag.
  • HA hemagluttinin
  • the recombinant protein can be isolated from the expressing cells by cell lysis followed by protein purification techniques such as affinity chromatography.
  • an antibody that specifically binds to FcRH which may be produced by methods that are well-known in the art, can be attached to a column and used to isolate FcRH.
  • the recombinant protein can, if desired, be purified further, e.g., by high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds., Elsevier, 1980).
  • the invention also provides a purified antibody or immunologic fragment thereof, wherein the antibody or fragment thereof selectively binds to an FcRH.
  • antibody encompasses, but is not limited to, whole immunoglobulin (i.e., an intact antibody) of any class.
  • Native antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges.
  • Each heavy chain has at one end a variable domain (V(H)) followed by a number of constant domains.
  • Each light chain has a variable domain at one end (V( )) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.
  • Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains.
  • the light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (k) and lambda (1), based on the amino acid sequences of their constant domains.
  • immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these maybe further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA- 2.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
  • variable is used herein to describe certain portions of the variable domains that differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen.
  • variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains.
  • CDRs complementarity determining regions
  • FR framework
  • the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a b-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the b-sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies (see Kabat E. A. et al., "Sequences of Proteins of Immunological Interest” National Institutes of Health, Bethesda, Md. (1987)).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody- dependent cellular toxicity.
  • the term "antibody or fragments thereof can also encompass chimeric antibodies and hybrid antibodies, with dual or multiple antigen or epitope specificities, and fragments, such as F(ab') 2 , Fab', Fab and the like, including hybrid fragments.
  • fragments of the antibodies that retain the ability to bind their specific antigens are provided.
  • fragments of antibodies which maintain FcRH binding activity are included within the meaning of the term "antibody or fragment thereof.”
  • Such antibodies and fragments can be made by techniques known in the art and can be screened for specificity and activity according to the methods set forth in the Examples and in general methods for producing antibodies and screening antibodies for specificity and activity (See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).
  • antibody or fragments thereof conjugates of antibody fragments and antigen binding proteins (single chain antibodies) as described, for example, in U.S. Pat. No. 4,704,692, the contents of which are hereby inco ⁇ orated by reference .
  • the antibody is a monoclonal antibody.
  • monoclonal antibody refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
  • Monoclonal antibodies of the invention may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975) or Harlow and Lane, Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988).
  • a hybridoma method a mouse or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the lymphocytes may be immunized in vitro.
  • the immunizing agent comprises an FcRH.
  • the generation of monoclonal antibodies has depended on the availability of purified protein or peptides for use as the immunogen.
  • DNA-based immunizations have shown promise as a way to elicit strong immune responses and generate monoclonal antibodies, hi this approach, DNA-based immunization can be used, wherein DNA encoding a portion of FcRH, preferably the N- or C- terminal region, is injected into the host animal according to methods known in the art.
  • peripheral blood lymphocytes are used in methods of producing monoclonal antibodies if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, "Monoclonal Antibodies: Principles and Practice” Academic Press, (1986) pp. 59-103).
  • Immortalized cell lines are usually transformed mammalian cells, including myeloma cells of rodent, bovine, equine, and human origin. Usually, rat or mouse myeloma cell lines are employed.
  • the hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif, and the American Type Culture Collection, RockviUe, Md. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., "Monoclonal Antibody Production Techniques and Applications” Marcel Dekker, Inc., New York, (1987) pp. 51-63).
  • the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against an FcRH.
  • the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the clones may be subcloned by limiting dilution or FACS sorting procedures and grown by standard methods. Suitable culture media for this pu ⁇ ose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
  • the monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • the monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567.
  • DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells of the invention serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, plasmacytoma cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, plasmacytoma cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat.
  • non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for FcRH and another antigen-combining site having specificity for a different antigen.
  • Digestion of antibodies to produce fragments thereof, particularly, Fab fragments can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994, U.S. Pat. No. 4,342,566, and Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, (1988). Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment, called the F(ab') 2 fragment, that has two antigen combining sites and is still capable of cross-linking antigen.
  • the Fab fragments produced in the antibody digestion also contain the constant domains of the light chain and the first constant domain of the heavy chain.
  • Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain domain including one or more cysteines from the antibody hinge region.
  • the F(ab') fragment is a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge at the hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • Antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • An isolated immunogenically specific epitope or fragment of the antibody is also provided.
  • a specific immunogenic epitope of the antibody can be isolated from the whole antibody by chemical or mechanical disruption of the molecule. The purified fragments thus obtained can be tested to determine their immunogenicity and specificity by the methods taught herein.
  • Immunoreactive epitopes of the antibody can also be synthesized directly.
  • An immunoreactive fragment is defined as an amino acid sequence of at least about two to five consecutive amino acids derived from the antibody amino acid sequence.
  • One method of producing proteins comprising the antibodies of the present invention is to link two or more peptides or polypeptides together by protein chemistry techniques.
  • peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyl- oxycarbonyl) or Boc (tert -butyloxycarbonoyl) chemistry. (Applied Biosystems, Inc., Foster City, CA).
  • Fmoc (9-fluorenylmethyl- oxycarbonyl) or Boc (tert -butyloxycarbonoyl) chemistry. Applied Biosystems, Inc., Foster City, CA.
  • a peptide or polypeptide corresponding to the antibody of the present invention can be synthesized by standard chemical reactions.
  • a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of an antibody can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group that is functionally blocked on the other fragment.
  • peptide condensation reactions By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof.
  • the peptide or polypeptide can by independently synthesized in vivo as described above. Once isolated, these independent peptides or polypeptides may be linked to form an antibody or fragment thereof via similar peptide condensation reactions.
  • enzymatic ligation of cloned or synthetic peptide segments can allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L et al., Biochemistry, 30:4151 (1991)).
  • native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson et al.
  • the first step is the chemoselective reaction of an unprotected synthetic peptide- ⁇ -thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site.
  • IL-8 human interleukin 8
  • unprotected peptide segments can be chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (non-peptide) bond (Schnolzer, M et al. Science, 256:221 (1992)).
  • This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton RC et al. Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257-267
  • the invention also provides fragments of antibodies that have bioactivity.
  • the polypeptide fragments of the present invention can be recombinant proteins obtained by cloning nucleic acids encoding the polypeptide in an expression system capable of producing the polypeptide fragments thereof, such as an adenoviras or baculoviras expression system.
  • an adenoviras or baculoviras expression system capable of producing the polypeptide fragments thereof.
  • one can determine the active domain of an antibody from a specific hybridoma that can cause a biological effect associated with the interaction of the antibody with FcRH.
  • amino acids found to not contribute to either the activity or the binding specificity or affinity of the antibody can be deleted without a loss in the respective activity.
  • amino or carboxy-terminal amino acids can be sequentially removed from either the native or the modified non-immunoglobulin molecule or the immunoglobulin molecule and the respective activity assayed in one of many available assays
  • a fragment of an antibody can comprise a modified antibody wherein at least one amino acid has been substituted for the naturally occurring amino acid at a specific position, and a portion of either amino terminal or carboxy terminal amino acids, or even an internal region of the antibody, has been replaced with a polypeptide fragment or other moiety, such as biotin, which can facilitate in the purification of the modified antibody.
  • a modified antibody can be fused to a maltose binding protein, through either peptide chemistry of cloning the respective nucleic acids encoding the two polypeptide fragments into an expression vector such that the expression of the coding region results in a hybrid polypeptide.
  • the hybrid polypeptide can be affinity purified by passing it over an amylose affinity column, and the modified antibody receptor can then be separated from the maltose binding region by cleaving the hybrid polypeptide with the specific protease factor Xa. (See, for example, New England Biolabs Product Catalog, 1996, pg. 164.).
  • the fragments can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove or add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide.
  • the phrase "specific binding” or “selective binding” refers to a binding reaction which is determinative of the presence of the FcRH in a heterogeneous population of proteins and other biologies.
  • the antibodies or fragments thereof of the present invention bind to a particular FcRH (e.g, human FcRH 1 or any variant thereof), fragment, or variant thereof and do not bind in a significant amount to other proteins (e.g, human FcRH 2, 3, 4, 5, or 6), present in the subject.
  • the absence of binding in the present invention is concisderd to be binding that is less than 1.5 times background (i.e., the level of non-specific binding or slightly above non-specific binding levels),
  • the purified antibody selectively binds to the FcRH comprising a cytoplasmic region with more than 107 or less than 104 amino acids, a transmembrane region, and an extracellular region. More specifically, the antibody in alternative embodiments selectively binds FcRHl but not FcRH2-6; selectively binds FcRH2 but not 1 or 3-6; selectively binds FcRH3 but not FcRHl-2 or 4-6; selectively binds FcRH6 but not 1-5.
  • the antibody selectively binds a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, 21, or 2, or a subset thereof, but not to polypeptides comprising the amino acid of SEQ ID NO:3, 22, 4, 5, 23, 24, 6, 25,
  • the purified antibody binds to the FcRH comprising the amino acid sequence of SEQ ID NO:3, 22, or 4, but not to the FcRH comprising the amino acid of SEQ ID NO: 1 , 21 , 2, 5, 23, 24, 6, 25, 26, 27, or 28.
  • the antibodies of the present invention may bind only moFcRHl , but not moFcRH 2 or moFcRH3 ; may bind only FcRH2 and not FcRHl or FcRH3, and may bind only FcRH3 and not FcRHl orFcRH2.
  • the antibody binds the extracellular region of one or more FcRHs and in other embodiments the antibody binds the cytoplasmic region of one or more FcRHs. In other embodiments the antibody may selectively bind one isoform of a FcRH. For example, the antibody may bind a polypeptide having the amino acid sequence of SEQ ED NO:23 but not the SEQ ED NO:24 or vice versa. Furthermore, the antibody can bind to moFcRHl having the amino acid sequence of SEQ ID NO:70, but not to a moFcRHl having amino acid sequence of SEQ ID NO:68.
  • the antibody may selectively bind a moFcRH2 with a transmembrane region (e.g, having amino acid sequence of SEQ ED NO:73), but not bind to a moFcRH2 lacking a transmembrane region (e.g, having the amino acid sequence of 77).
  • a moFcRH2 with a transmembrane region e.g, having amino acid sequence of SEQ ED NO:73
  • a transmembrane region e.g, having amino acid sequence of SEQ ED NO:73
  • the antibody of the invention can selectively bind moFcRH but not human, or vice versa.
  • immunoassay formats may be used to select antibodies that selectively bind with a particular protein, variant, or fragment.
  • solid- phase ELISA immunoassays are routinely used to select antibodies selectively immunoreactive with a protein, variant, or fragment thereof. See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988), for a description of immunoassay formats and conditions that could be used to determine selective binding.
  • the binding affinity of a monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem, 107:220 (1980).
  • the invention also provides an antibody reagent kit comprising the antibody or fragment thereof of the invention and reagents for detecting binding of the antibody or fragment thereof to a ligand.
  • the kit can further comprise containers containing the antibody or fragment thereof of the invention and containers containing the reagents.
  • the ligand is a FcRH, variant, or fragment thereof.
  • the kit can detect the presence of one or more FcRHs specifically reactive with the antibody or an immunoreactive fragment thereof.
  • the kit can include an antibody bound to a substrate, a secondary antibody reactive with the antigen and a reagent for detecting a reaction of the secondary antibody with the antigen.
  • a kit can be an ELISA kit and can comprise the substrate, primary and secondary antibodies when appropriate, and any other necessary reagents such as detectable moieties, enzyme substrates and color reagents as described above.
  • the diagnostic kit can, alternatively, be an immunoblot kit generally comprising the components and reagents described herein.
  • the kit could be a radioimmunoassay kit, a Western blot assay kit, an immunohistological assay kit, an immunocytochemical assay kit, a dot blot assay kit, a fluorescence polarization assay kit, a scintillation proximity assay kit, a homogeneous time resolved fluorescence assay kit, or a BIAcore analysis kit.
  • methods of detecting an FcRH or antigen antibody complexes can comprise an ELISA (competition or sandwich), a radioimmunoassay, a Western blot assay, an immunohistological assay, an immunocytochemical assay, a dot blot assay, a fluorescence polarization assay (Jolley (1981); Jiskoot et al (1991); Seethala et al. (1998); Bicamumpaka et al. (1998)), a scintillation proximity assay (Amersham Life Science (1995) Proximity News.
  • the antigen/antibody complex is detectably tagged either directly or indirectly.
  • Any desired tag can be utilized, such as a fluorescent tag, a radiolabel, a magnetic tag, or an enzymatic reaction product.
  • the antibody or fragment is a humanized antibody or a fully human antibody.
  • the antibodies can also be generated in other species and
  • Fully human antibodies for administration to humans.
  • fully human antibodies can also be made by immunizing a mice or other species capable of making a fully human antibody (e.g, mice genetically modified to produce human antibodies), screening clones that bind FcRH.
  • a mice or other species capable of making a fully human antibody e.g, mice genetically modified to produce human antibodies
  • screening clones that bind FcRH e.g., Lonberg and Huszar (1995) Human antibodies from transgenic mice, Int. Rev. Immunol. 13:65-93, which is inco ⁇ orated herein by reference in its entirety for methods of producing fully human antibodies.
  • the term “humanized” and “fully human” in relation to antibodies relate to any antibody which is expected to elicit a therapeutically tolerable weak immunogenic response in a human subject.
  • Humanized forms of non-human (e.g, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' ,
  • F(ab') 2 or other antigen-binding subsequences of antibodies which contain minimal sequence derived from non-human immunoglobulin.
  • Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • donor antibody such as mouse, rat or rabbit having the desired specificity, affinity and capacity.
  • Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • Humanized antibodies may also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, hi general, the humanized antibody will comprise substantially all or at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al. Nature, 321:522-525 (1986); Riechmann et al. Nature, 332:323-327 (1988); and Presta, Curr. Op. Struct. Biol, 2:593-596 (1992)).
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al. Nature, 321:522-525 (1986); Riechmann et al. Nature, 332:323-327 (1988); Verhoeyen et al. Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • variable domains both light and heavy
  • the choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important in order to reduce antigenicity.
  • the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences.
  • the human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al, J. Immunol, 151:2296 (1993) and Chothia et al, J. Mol. Biol, 196:901 (1987)).
  • Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains.
  • the same framework may be used for several different humanized antibodies (Carter et al, Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al, J. Immunol, 151:2623 (1993)).
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences.
  • Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probable three- dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • the CDR residues are directly and most substantially involved in influencing antigen binding (see, WO 94/04679 published 3 Mar. 1994).
  • Transgenic animals e.g, mice
  • J(H) antibody heavy chain joining region
  • Human antibodies can also be produced in phage display libraries (Hoogenboom et al, J. Mol. Biol, 227:381 (1991); Marks et al, J. Mol. Biol, 222:581 (1991)).
  • the techniques of Cote et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al, J. Immunol, 147(1):86- 95 (1991)).
  • the antibody or fragment thereof is a single chain antibody. In another embodiment, the antibody or fragment is labeled. Optionally the antibody or fragment is conjugated or fused with a toxin or fragment thereof. Examples of the toxin or toxin moiety include diphtheria, ricin, and modifications thereof.
  • the invention provides uses of the reagents described herein in in vitro and in vivo methods of diagnosing and treating a malignancy of hematopoietic cell lineage or an autoimmune disease in a subject.
  • the reagents of the present invention are also useful in screening for disease manifestations. Such screening may be useful even before the onset of other clinical symptoms and could be used to screening subjects at risk for disease, so that prophylactic treatment can be started before the manifestation of other signs or symptoms.
  • malignancy is meant a tumor or neoplasm whose cells possess one or more nuclear or cytoplasmic abnormalities, including, for example, high nuclear to cytoplasmic ratio, prominent nucleolar/nucleoli variations, variations in nuclear size, abnormal mitotic figures, or multinucleation.
  • Malignancies of hematopoietic cell lineage include, but are not limited to, myelomas, leukemias, lymphomas (Hodgkin's and non-Hodgkin's forms), T-cell malignancies, B-cell malignancies, and lymphosarcomas or other malignancies described in the REAL classification system or the World Health Organization Classification of Hematologic Malignancies.
  • FcRHs can be diagnostic for a particular malignancy of hematopoietic cell linage or can be diagnostic for a particular form of a malignancy (e.g, a specific form of leukemia).
  • inflammatory and autoimmune diseases illustratively including systemic lupus erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-versus-host disease, Sj ⁇ gren's syndrome, pernicious anemia, Addison disease, scleroderma, Goodpasture's syndrome, Crohn's disease, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Basedow's disease, thrombopenia pu ⁇ ura, insulin-dependent diabetes mellitus, allergy; asthma, atopic disease; arteriosclerosis; myocarditis; cardiomyopathy; glomemlar nephritis; hypoplastic anemia; rejection after organ transplantation and numerous malignancies of lung, prostate, liver, ovary, colon, cervix, lymphatic and breast tissues.
  • the diagnostic methods comprise the steps of contacting a biological sample of the subject with an antibody or nucleic acid of the invention under conditions that allow the antibody to bind to cells of hematopoietic cell lineage or allow the nucleic acid to hybridize, preferably under stringent conditions, with nucleic acids of the biological sample; and detecting the amount or pattern of binding. Changes in the amount or pattern of binding as compared to binding in a control sample indicate a malignancy or an inflammatory or autoimmune disease.
  • the antibody used in the diagnostic method can selectively bind with an FcRH having the amino acid sequence of SEQ ED NO: 1, 21, 2, 3, 22, 4, 5, 24, or 6.
  • the detecting step of the diagnostic method can be selected from methods routine in the art.
  • the detection step can be performed in vivo using a noninvasive medical technique such as radiography, fluoroscopy, sonography, imaging techniques such as magnetic resonance imaging, and the like.
  • In vitro detection methods can be used to detect bound antibody or fragment thereof in an ELISA, RIA, immunohistochemically, FACS, IHC, FISH, or similar assays.
  • biological sample refers to a sample from any organism.
  • the sample can be, but is not limited to, peripheral blood, plasma, urine, saliva, gastric secretion, feces, bone marrow specimens, primary tumors, embedded tissue sections, frozen tissue sections, cell preparations, cytological preparations, exfoliate samples
  • the biological sample of this invention can also be whole cells or cell organelles (e.g, nuclei).
  • the sample can be unfixed or fixed according to standard protocols widely available in the art and can also be embedded in a suitable medium for preparation of the sample.
  • the sample can be embedded in paraffin or other suitable medium (e.g, epoxy or acrylamide) to facilitate preparation of the biological specimen for the detection methods of this invention.
  • the invention also provides a method of treating a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject, comprising contacting the subject's malignant cells or inflammatory cells with a therapeutically effective amount of a reagent (e.g, an antibody or nucleic acid) or a therapeutic composition of a reagent of the invention.
  • a reagent e.g, an antibody or nucleic acid
  • the contacting step can occur by administration of the reagent or composition using any number of means available in the art.
  • the reagent or composition is administered to the subject transdermally (e.g, by a transdermal patch or a topically applied cream, ointment, or the like), orally, subcutaneously, intrapulmonaryily, transmucosally, intraperitoneally, intrauterinely, sublingually, intrathecally, intramuscularly, intraarticularly, etc. using conventional methods, i addition, the reagent or composition can be administered via injectable depot routes such as by using 1-, 3-, or 6-month depot injectable or biodegrable materials and methods.
  • the amount of the reagent administered or the schedule for administration will vary among individuals based on age, size, weight, condition to be treated, mode of administration, and the severity of the condition.
  • dosages are best optimized by the practicing physician and methods for determining dosage are described, for example in Remington's Pharmaceutical Science, latest edition. Guidance in selecting appropriate doses for antibodies is found in the literature on therapeutic uses of antibodies, e.g.
  • a typical dose of the antibody used alone might range from about 1 ⁇ g/kg to up to 100 mg/kg of body weight or more per day, and preferably 1 ⁇ g/kg to up to 1 mg/kg, depending on the factors mentioned above.
  • An intravenous injection of the antibody or fragment thereof could be lOng-lg of antibody or fragment thereof, and preferably lOng-lmg depending on the factors mentioned above.
  • a typical quantity of antibody ranges from lpg tolmg .
  • the local injection would be at an antibody concentration of 1-100 ⁇ g/ml, and preferably 1-20 ⁇ g/ml.
  • nucleic acids of the invention can delivered to cells in a variety of ways.
  • the dosage for administration of adenoviras to humans can range from about 10 ⁇ to 10- ⁇ plaque forming units (pfu) per injection, but can be as high as l ⁇ l2 pfu per injection.
  • a subject will receive a single injection. If additional injections are necessary, they can be repeated at six month intervals for an indefinite period and/or until the efficacy of the treatment has been established.
  • the efficacy of treatment can be determined by evaluating the clinical parameters.
  • nucleic acid or vector The exact amount of the nucleic acid or vector required will vary as described above. Thus, it is not possible to specify an exact amount for every nucleic acid or vector. An appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
  • the invention further provides a therapeutic composition of the reagent of the invention.
  • a composition typically contains from about 0.1 to 90% by weight (such as 1 to 20% or 1 to 10%) of a therapeutic agent of the invention in a pharmaceutically acceptable carrier.
  • Solid formulations of the compositions for oral administration may contain suitable carriers or excipients, such as com starch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, or alginic acid.
  • Disintegrators that can be used include, without limitation, microcrystalline cellulose, corn starch, sodium starch, glycolate, and alginic acid.
  • Tablet binders that may be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolindone (PovidoneTM), hydroxypropyl methylcellulose, sucrose, starch, and ethylcellulose.
  • Lubricants that may be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.
  • Liquid formulations for oral administration prepared in water or other aqueous vehicles may contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol.
  • the liquid formulations may also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.
  • Various liquid and powder formulations can be prepared by conventional methods for inhalation into the lungs of the mammal to be treated.
  • Injectable formulations of the compositions may contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).
  • water soluble version of the compounds may be administered by the drip method, whereby a pharmaceutical formulation containing the antifungal agent and a physiologically acceptable excipient is infused.
  • Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients.
  • Intramuscular preparations e.g, a sterile formulation of a suitable soluble salt form of the compounds
  • a pharmaceutical excipient such as water-for- injection, 0.9% saline, or 5% glucose solution.
  • a suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (e.g, ethy; oleate).
  • a topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, e.g, 5 to 10%, in a carrier such as a pharmaceutical cream base.
  • a carrier such as a pharmaceutical cream base.
  • formulations for topical use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles.
  • the optimal percentage of the therapeutic agent in each pharmaceutical formulation varies according to the formulation itself and the therapeutic effect desired in the specific pathologies and correlated therapeutic regimens.
  • the effectiveness of the method of treatment can be assessed by monitoring the patient for known signs or symptoms of the conditions being treated. For example, in the treatment of a malignancy of hematopoietic cell lineage, the reduction or stabilization of the number of abnormally proliferative cells would indicate successful treatment, i the treatment of arthritis, for example, a reduction in the amount of joint inflammation would indicate successful treatment.
  • therapeutically effective is meant an amount that provides the desired treatment effect.
  • the invention further provides a method of modulating a humoral immune response in a subject, comprising administering to the subject an isolated FcRH, an antibody, or nucleic acid of the invention. By “modulation” is meant either up- regulating or down-regulating.
  • PCR products were ligated into the pCR2.1 TOPO T/A vector (Invitrogen). Inserts were DNA-sequenced on both strands by the dideoxy chain termination method using Thermo Sequenase (Amersham Pharmacia) and an automated sequencer (Li-Cor, Lincoln, NE). Nucleotide and amino acid sequence alignment was analyzed with a DNASTAR (Madison, WI) software package, and homology searches were performed by using BLAST (Altschul, S. F. et al. (1990) J. Mol. Biol. 215, 403-410). RNA blot analysis was subsequently performed.
  • BLAST Altschul, S. F. et al. (1990) J. Mol. Biol. 215, 403-410.
  • Northern blots (CLONTECH) were hybridized with 32P-dCTP-labeled probes: a 528-bp EcoRI fragment corresponding to the 5' untranslated (UT)-ECl regions of the FcRH3 cDNA, a 200-bp PCR product corresponding to a portion of the 3' UT region of the FcRH2 cDNA, and a 257-bp PCR product corresponding to a portion of the 3' UT region of the FcRHl cDNA.
  • Membranes were hybridized for 1 h at 65°C, washed, and exposed to x-ray film (Kubagawa, H. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 5261-5266).
  • RT-PCR Reverse transcription
  • FcRHl forward 5'-CTC AAC TTC ACA GTG CCT ACT GGG-3' (SEQ ID NO:53) and reverse, 5'-TCC TGC AGA GTC ACT AAC CTT GAG-3' (SEQ ID NO:54);
  • FcRH2 forward 5'-CCA GTG TAT GTC AAT GTG GGC TCT G (SEQ ED NO:55) and reverse, 5'-CAT TCT TCC CTC AAA TCT TTA CAC-3' (SEQ DD NO:56);
  • FcRH3 forward 5'-CAG CAC GTG GAT TCG AGT CAC-3' (SEQ ID NO:57) and reverse, 5'- CAG ATC TGG GAA TAA ATC GGG TTG-3' (SEQ ID NO:58)
  • FcRHl forward 5'- TCT
  • Each amplification reaction underwent initial denaturation at 94° for 5 min followed by 35 cycles of denaturation at 94° for 30 s, annealing at 60° for 30 s, extension at 72° for 1 min, and final extension at 72° for 7 min.
  • Amplified products were visualized in 1% agarose gels containing ethidium bromide and documented with the Bio-Rad Fluor-S hnager.
  • the following human cell lines were used: REH and Nairn 16 pro-B cell lines
  • a consensus sequence was generated that corresponds to the GenBank-derived amino terminal sequences of the second Ig-like domains of FcR (Fc ⁇ RI and Fc ⁇ RII/i ⁇ ) and the third Ig-like domain of the polymeric Ig receptor:GEPIXLRCHSW ⁇ -DKXLXKVTYXQNGKAXKFFH (SEQ ID NO:63).
  • a search of the National Center for Biotechnology Information protein database with this sequence identified two overlapping human genomic bacterial artificial chromosome (BAC) clones, AL135929 and AL356276, which are located at lq21.2-22.
  • BAC human genomic bacterial artificial chromosome
  • the second clone contained three putative Ig superfamily genes encoding complementary amino acid sequences that were designated FcRHl, FcRH2, and FcRH3. See Figure 1. The predicted amino acid sequences of these gene segments shared 23-57% identity with each other and 14-28%) identity with human Fc ⁇ RI (CD64). Further analysis of the
  • FcRH locus led to the identification of two additional genes (FcRH4, and FcRH5) and one pseudogene (FcRH4 ⁇ ), immediately centromeric of FcRHl -3, two of which have recently been described as ERTA1 (FcRH4) and IRTA2 (FcRH5) (Hatzivassiliou, G. et al. (2001) Immunity 14, 277-289).
  • ERTA1 FcRH4
  • IRTA2 FcRH5
  • FcRHl, FcRH2, and FcRH3 cDNAs were isolated by RACE-PCR from a human lymph node cDNA library in both 5' and 3' directions. Full-length cDNAs of the coding regions for FcRHl, FcRH2, and FcRH3 were obtained by end-to-end PCR using unique primers generated from the cDNA sequences delineated for the 5' UT and 3'UT regions.
  • FcRHl has a long cytoplasmic tail containing three potential ITAMs, the first and third of which fit the consensus sequence (E/D)-X-X-Y-X-X-(L/I)-X 6 . 8 -Y-X-X-(L/I) (SEQ ID NO:64, with six amino acid between the consensus sequences; SEQ ID NO:65, with seven amino acid residues between the consensus sequences; and SEQ ID NO: 66, with eight amino acid residues between the consensus sequences), whereas, the second has only one tyrosine residue.
  • FcRH2 contains one potential ITAM and two ITIM consensus sequences (I/V/L/S)-X-Y-X-X-(L/V) (SEQ ID NO:67) separated by 22 amino acids.
  • FcRH3 has the longest cytoplasmic tail. It contains one potential ITAM, one ITIM, and another potential ITAM that also has a single tyrosine residue.
  • RNA blot analysis with gene-specific probes was performed on 16 human tissues, including six primary or secondary lymphoid tissues. RNA blots were analyzed with discriminating ⁇ 32 P-dCTP -labeled probes generated from the respective FcRH cDNAs.
  • the following probes were used: (Top) a PCR-generated, 257-bp probe specific to the 3' UT region of FcRHl; (Middle) a PCR-generated, 290-b ⁇ probe corresponding to the 3' UT region of FcRH2; and (Bottom) a 528-bp EcoRI-digested fragment of the 5' end of the FcRH3 cDNA corresponding to its 5' UT region, SI, S2, and EC1 domains. The relative mRNA abundance was indicated by ⁇ -actin probe. All three FcRH gene probes hybridized with transcripts in the secondary lymphoid organs, spleen and lymph node.
  • FcRH3 probe hybridized with about 3.5-kb, about 5.5-kb, and about 7.0-kb transcripts chiefly in spleen and lymph node. These also were seen, albeit in lesser abundance, in peripheral blood lymphocytes, thymus, and bone marrow samples. Additionally, a unique transcript of about 1.35 kb was evident in skeletal muscle. These results indicated expression of FcRHl, FcRH2, and FcRH3 in peripheral lymphoid organs, whereas tissue specific differences in alt +ernative splicing or polyadenylation were suggested by the differential expression of transcripts with variable size in nonlymphoid tissues. RTPCR analysis to date of non-lymphoid tissue skeletal muscle, however, does not reveal transcripts despite the Northern analysis results.
  • FcRH expression was examined by RT-PCR analysis of cell lines representing different hematopoietic lineages, FcRHl, FcRH2, and FcRH3 expression + was found in every mature B cell line tested (Table 2).
  • FcRH2 and FcRH3 expression was limited to the mature B cell lines and not seen in the other types of cells examined.
  • FcRHl expression was seen in pro-B, T, and myeloid cell lines, although not in an erythroid cell line.
  • FcRHl, FcRH2, and FcRH3 expression in cell lines was determined by RT-PCR.
  • FcRHl, FcRH2, FcRH3, and FcRH5 are expressed at relatively high levels in CD 19+ B cells, whereas FcRH4 was expressed at only trace levels.
  • FcRH3 expression was observed in CD3+ T cells whereas transcripts of FcRHl were barely detectable. FcRHl expression also was observed in circulating granulocytes.
  • tonsillar lymphocyte subpopulations were isolated.
  • the five discrete subpopulations of B lineage cells which can be distinguished by their differential expression of cell surface IgD and CD38, represent different stages in B cell differentiation: follicular mantle (IgD+CD38), pre-GC (IgD+CD38+), GC (IgDCD38+), memory (IgDCD38), and mature plasma cells (CD38 2 +) (Pascual, V. (1994) J. Exp. Med. 180: 329-339).
  • RT- PCR analysis of FcRHl -5 expression in tonsillar B cell subpopulations was performed.
  • Viable cells were magnetically sorted into CD19- non-B cells and CD19+ B cells. The latter were stained with anti-IgD and anti-CD38 mAbs, and the five subpopulations indicated (CD38- IgD-, CD38- IgD+, CD38+ IgD+, CD38+ IgD-, and CD38 2 +) were sorted by flow cytometry. RT-PCR analysis of FcRH transcripts in non-B cells and the B cell subpopulations was also performed. After cDNA preparation, PCR amplification was performed on the equivalent template of approximately 10 k cells. Glyceraldehyde- 3-phosphate dehydrogenase (GADPH) was amplified as a positive control.
  • GADPH Glyceraldehyde- 3-phosphate dehydrogenase
  • RT-PCR analysis indicated little or no expression of FcRH transcripts in the non-B lineage CD 19- cells, most of which are T cells.
  • CD 19+ subpopulations displayed coordinate expression of FcRHl, FcRH2, and FcRH3 transcripts in follicular mantle, na ⁇ ve, GC, and memory B cell subpopulations, but yielded no evidence of FcRH transcripts in pre-GC B cells or plasma cells.
  • FcRH4 transcripts were restricted to the follicular mantle and memory B cells, whereas FcRH5 expression extended to mature plasma cells.
  • the FcRHl gene consists of 11 exons and 10 introns spanning about 28 kb.
  • the first exon, 5' UT/S1 encodes the 5' UT region, the ATG translation initiation codon, and the first half of a split signal peptide.
  • S2 the second exon, is separated from 5' UT/S1 by a long intron of 12.9 kb and, like the neighboring FcRs, is
  • the extracellular region is encoded by three closely clustered exons, EC1-EC3, that code for the three Ig-like domains.
  • the membrane-proximal, transmembrane, and the proximal portion of the cytoplasmic domain are encoded by a single sixth exon, TM.
  • the cytoplasmic tail is encoded by five exons, CY1-CY5, and the CY5 also encodes the beginning of the 3' UT region.
  • FcRH2 contains 12 exons and 11 introns that span 30 kb. It also contains two exons that encode a split signal peptide, the first of which, 5'UT/S1, includes the 5' UT region, the ATG translation initiation codon, and first half of the signal peptide. The second exon, S2, is 21 bp in length. Exons 3-6 encode the four extracellular domains, EC1-EC4. The seventh exon encodes the membrane-proximal, transmembrane, and the proximal portion of the cytoplasmic domain. The FcRH2 cytoplasmic tail is encoded by five exons, CY1-CY5, the last exon of which includes the termination of the ORF and beginning of the 3' UT region.
  • the FcRH3 gene consists of 16 exons and 15 introns that span about 24 kb. Unlike FcRHl and FcRH2, its 5' UT region is encoded by two exons, 5' UT1 and a second, 5T T2/S1, that also encodes the ATG translation initiation codon and the beginning of the split signal peptide. The third exon, S2, is also 21 bp in length. Extracellular domains encoded by six exons, EC1-EC6, are followed by exon 10 that encodes the membrane-proximal, transmembrane, and the proximal portion of the cytoplasmic domain. The cytoplasmic tail is encoded by five exons, CY1-CY5; the last contains the beginning of the 3' UT region.
  • huFcRH ⁇ initial RT-PCR analysis of huFcRH ⁇ in human tissues and cell lines (as described in Example 1) reveals transcript expression in normal tonsil and lymph nodes.
  • expression of huFcRH ⁇ was identified in myeloid cell lines THP-1 (monocytic), U937 (myelomonocytic), and KG-1 (myelocytic). Limited expression if any was identified in the 207 pre-B cell line and the Daudi B cell line.
  • EXAMPLE 3 Generation of Transfectants and Antibodies Recombinant constracts for transfection and stable expression of huFcRHl-5 have been generated.
  • the constracts have been ligated into a CMV driven mammalian expression vector with and without green fluorescent protein (GFP) fusion at the carboxyl terminus.
  • GFP green fluorescent protein
  • Surface expression of huFcRHl and huFcRH3 was detected for both GFP and non-GFP forms by staining with antibody supernatant.
  • the antibody supernatant was derived from hybridomas generated by mice immunized with recombinant extracellular protein of the respective FcRH.
  • the constracts for huFcRH2, 4, and 5 have been detected by green fluorescence as well as surface expression for FcRH4.
  • Monoclonal antibodies have been generated, including, for example, an antibody that binds FcRHl .
  • the preliminary analysis of FACS staining for FcRHl expression with monoclonal antibody 1-5 A3 labeled with a FITC conjugate (mouse anti human FcRHl) in peripheral blood from normal volunteers indicates virtually all CD19+ B cells have huFcRHl expression, as do CD14+ monocytes and CD13+ granulocytes.
  • CD3+ T cells have limited to no expression of FcRHl.
  • Staining of B-CLL samples from two different patient peripheral blood samples indicates that virtually all CD5+/CD19+ B-CLL cells are positive for the FcRHl 1-5 A3 antigen.
  • By western blot analysis of recombinant protein for FcRHl-5 extracellular regions 1-5A3 appears specific for FcRHl. 1-5A3 also stains B cell lines Daudi and Raji.
  • MoFcRH 1-3 A family of three mouse Fc Receptor Homologs (MoFCRHs) were identified and cloned. Amino acid sequences from the membrane proximal Ig-like domains of huFcRHl-5 were used to identify putative mouse FcRH orthologs in the NCBI or Celera genomic, EST, and protein databases using the protein BLAST (BLASTP) and the translated nucleotide BLAST (TBLASTN) algorithms, respectively. The location of moFcR family is split between chromosomes 1 and 3 in regions syntenic with human chromosome lq21-23. See Figure 4. The mo FcRH are located on mouse Ch3. Approximate positions were determined from Genbank, Celera, and Mouse Genome Informatics databasesContigs of ESTs were generated to determine the putative cDNA sequences.
  • Genomic organization was determined by comparing cDNA clones generated from RACE PCR with GenBank and Celera genomic sequences. DNAStar software was used for analysis of exon-intron boundaries which were characterized by sequence comparison and the AG/GT rule. All three genes contain a split signal sequence with a 21bp S2 exon (exon 2) which is found in all FcR and huFcRH genes on human chromosone 1.
  • the mouse FcReceptor Homologs include secreted or type I transmembrane isolfrms that have unique cytoplasmic tails with potential activation and inhibition motifs. Their chromosomal location, Ig domain homology, and genomic organization indicate the mouse FcReceptor Homologs are orthologs of the huFcRH that have evolved a significant level of diversity. moFcRHl, moFcRH2, and moFcRH3 are predicted to encode secreted or type I transmembrane proteins based on their amino acid sequences.
  • moFcRHl has two secreted isoforms both of which have extracellular (EC) regions of four Ig-like domains with five potential sites for N-linked glycosylation.
  • One isoform is a fusion protein with a type B scavenger receptor domain containing 8 cysteines.
  • moFcRH2 has secreted and type I isoforms containing two Ig- like domains with five N-linked glycosylation sites.
  • the type I isoform has an uncharged transmembrane region which the secreted isoform lacks.
  • Both isoforms contain the cytoplasmic portion which is long in the transmembrane form and contains five tyrosines including a consensus sequence for one potential immunoreceptor tyrosine-based activating motif .
  • moFcRH3 contains five Ig-like domains with six potential sites of N-linked glycosylation. Its transmembrane domain is also uncharged and the cytoplasmic region contains one potential ITAM and one potential immunoreceptor tyrosine-based inhibitory motif.
  • the amino acid (aa) length of individual regions and full length (FL) isoforms, as well as approximate molecular weight (MW) in Daltons (Da) is indicated in the stractural diagram of Figure 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ('ITIMs' or 'ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.

Description

MEMBERS OF THE FC RECEPTOR HOMOLOG GENE FAMILY (FCRH1-3, 6), RELATED REAGENTS, AND USES THEREOF
This application claims the benefit of U.S. Provisional Application No. 60/367,667, filed March 25, 2002.
ACKNOWLEDGEMENTS This invention was made with government support under Grants 2R37 and AI39816 awarded by NIAID. The government has certain rights in the invention.
FIELD OF THE INVENTION This invention relates generally to immunology and modulation of immunologic responses in the context of inflammatory diseases and cancer.
BACKGROUND OF THE INVENTION
Receptors for the Fc region (FcRs) of Igs have broad tissue distribution patterns and can modulate cellular and humoral immunity by linking their antibody ligands with effector cells of the immune system (Ravetch, J. V. & Kinet, J.-P. (1991) Aimu. Rev. Immunol. 9, 457-492; Daeron, M. (1997) Annu. Rev. Immunol. 15, 203-234. These cellular receptors have the ability to sense humoral concentrations of antibody, initiate cellular responses in host defense, and participate in autoimmune disorders (Ravetch, J. V. & Bolland, S. (2001) Annu. Rev. Immunol. 19, 275-290). Their diverse regulatory roles depend on the Ig isotype specificity and cellular distribution of the individual FcR. These Ig superfamily members share similarities in their ligand binding subunits, and they may have inhibitory or activating signaling motifs in their intracellular domains or instead pair with signal transducing subunits possessing activating signaling motifs.
Recently, characterization of FcR homologs in mice, the paired Ig-like receptors (Kubagawa, H. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 5261- 5266; Hayami, K. et al. (1997) J. Biol. Chem. 272, 7320-7327), and their relatives in humans the Ig-like transcripts/ leucocyte Ig-like receptors (Borges, L. et al. (1997) J. Immunol. 159, 5192-5196; Samaridis, J. & Colonna, M. (1997) Eur. J. Immunol. 27, 660-665) have been elucidated. This multigene family, which includes the FcαR (Kremer, E. J. et al. (1992) Hum. Genet. 89, 107-108) and the natural killer cell Ig-like receptors (Wagtmann, N. et al. (1997) Curr. Biol. 7, 615-618), is located in a human chromosome 19ql3 region known as the leucocyte receptor complex (LRC) (Wende, H. et al. (1999) Mamm. Genome 10, 154-160; Wilson, M. J. et al. (2000) Proc. Natl. Acad. Sci. USA 97, 4778-4783). These Ig-like multigene families belong to a larger class of receptors characterized by their possession of common cytoplasmic tyrosine-based signaling motifs. These can be either immunoreceptor tyrosine-based activation motifs (ITAMs) containing two repeats of the consensus sequence Y-X-X-L/I spaced by 6-8 amino acids (E/D)-X-X-Y-X-X-(L/I)-X6-8-Y-X-X-(L/I) (SEQ ID NO:64, with six amino acid between the consensus sequences; SEQ ID NO:65, with seven amino acid residues between the consensus sequences; and SEQ ID NO:66, with eight amino acid residues between the consensus sequences) or immunoreceptor tyrosine-based inhibitory motifs (IT s) with a 6-amino acid consensus sequence (I/V/L/S)-X-Y-X-X-(L/V) (SEQ ID NO:67) (Reth, M. (1992) Annu. Rev. Immunol. 10, 97-121; Vely, F. & Vivier, E. (1997) J. Immunol. 159, 2075-2077; Ravetch, J. V. & Lanier, L. L. (2000) Science 290, 84-89; Gergely, J. et al. (1999) Immunol. Lett. 68, 3-15). The phylogenetic conservation of these types of receptors in birds (Dennis, G. et al. (2000) Proc. Natl. Acad. Sci. USA
97, 13245-13250) and bony fish (Yoder, J. A. et al. (2001) Proc. Natl. Acad. Sci. USA
98, 6771-6717) is indicative of their biological value. After ligand binding of the activating receptor complexes, IT AM tyrosines are rapidly phosphorylated by Src family kinases to initiate a cascade of signaling events that trigger cellular activation. In the case of ITIM-bearing receptors, the tyrosines provide a docking site for phosphatases containing Src homology 2 domains that can abrogate cellular activation (Long, E. O. (1999) Annu. Rev. Immunol. 17, 875-904; Unkeless, J. C. & Jin, J. (1997) Curr. Opin. Immunol. 9, 338-343). The balance in the utilization of these activating and inhibitory receptor pairs can serve to modulate cellular responses to a variety of stimuli. The genes encoding the classical FcγRs, FcγRI, FcγRII, FcγRm, and FcεRI, lie on the long arm of chromosome 1 (lq21-23) near the polymeric Ig receptor (plgR) and Fcα/μR genes (lq32) (20-23). Members of this FcR subfamily have relatively low extracellular homology with the FcR-related genes that reside in the LRC on chromosome 19. Like the FcγR- and FcεR-activating receptors, the ligand binding chain of the FcαR coassociates with the ITAM containing FcR common γ-chain (Pfefferkorn, L. C. & Yeaman, G. R. (1994) J. Immunol. 153, 3228-3236; Morton, E.
C. et al. (1995) J. Biol. Chem. 270, 29781-29787). New members of the FcR family were sought which could have diverse signally properties and oncogenic potential.
SUMMARY OF THE INVENTION
In accordance with the purpose(s) of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to members of a cluster of FcR and FcR gene relatives encoded, for example, by genes in the human chromosome lq21-23 region, or analogous region in non-human subjects. The members are Type I transmembrane receptors, or alternatively spliced forms thereof, with homology to the FcR family and are referred to herein as FcRHs. Each FcRH can comprise an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ("ITIMs" or "ITAMs). The invention relates to polypeptides corresponding to isolated FcRHs (e.g., huFcRH 1, 2, 3, and 6 and moFcRHl, 2, and 3), as well as fragments and isoforms thereof. The invention further relates to nucleic acids that encode the FcRHs, as well as hybridization probes related thereto and complementary sequences. The invention further provides vectors and cells related to the nucleic acids of the invention. The invention further relates to making an FcRH, or a fragment or variant thereof, comprising culturing a cell comprising a vector of the invention under conditions permitting expression of the FcRH. The invention also provides an antibody reagent kit comprising the antibody, or a fragment or variant thereof, and reagents for detecting binding of the antibody, fragment, or antibody variant to a ligand. The invention further relates to uses of the polypeptides, nucleic acids and antibodies of the invention. For example, the invention relates to methods of diagnosing and methods of treating a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject. The invention also relates to modulation of a humoral immune response in a subject. Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate (one) several embodiment(s) of the invention and together with the description, serve to explain the principles of the invention.
Figure 1 shows the relative position of the FcRH locus within the FcR cluster on chromosome 1. The cytogenetic location of the FcR genes is approximated from the GenBank Mapview database. The BAC clones (4, GenBank accession no. AL139409; 3, GenBank accession no. AL356276; 2, GenBank accession no. AL135929; and 1, GenBank accession no. AL353721) that span the locus are oriented in relation to their respective FcRH genes (shaded area). Figure 2 shows the structural and sequence diversity of FcRHl, FcRH2, and
FcRH3. Figure 2 A is a schematic representation of FcRH molecules. The three cDNAs encode type I transmembrane proteins with similar extracellular domains, but different cytoplasmic regions. The extracellular (EC) regions contain different numbers of C2- like Ig domains and potential sites of N-linked glycosylation. The transmembrane (TM) domains are uncharged, except in the case of FcRH 1. The cytoplasmic (CY) region of FcRHl contains two ITAMs (light gray boxes) and one ITAM-like region (small, lined box), whereas FcRH2 contains one ITAM and two ITIMs (dark gray boxes). FcRH3 has a long cytoplasmic tail with one ITAM, one ITIM, and an ITAM-like region. The amino acid length of each region is indicated. Figure 2B shows the multiple alignment comparison of FcRHl, FcRH2, and FcRH3 amino acid sequences (one-letter code) based on the FcRH3 sequence. Amino acid identity is represented by dots, and gaps are indicated by dashes. Predicted N-linked glycosylation sites and transmembrane domains are underlined in black. Consensus ITAM (bold) and ITIM (bold, underlined) motifs are indicated. Putative structural domains are labeled: SP, signal peptide; EC, extracellular domain; MP-TM, membrane proximal-transmembrane; and CY, cytoplasmic regions. Amino acid lengths are indicated in parentheses.
Figure 3 shows a composite analysis of the extracellular homology among FcRH and FcR family members. Pairwise analysis of individual Ig-like subunits was performed with the CLUSTAL method algorithm using FcRH3 as the index of comparison. Individual homologous domains are coded to indicate relatedness. Percent amino acid identities for related domains are indicated and aligned in relation to the comparative FcRH3 subunit. The amino acid identity for the membrane proximal domains (light gray subunits) of FcRH5 are provided as the range of identity for all individually related domains. Comparisons that are not applicable are left blank. Amino acid sequences were derived from IRTA1 (GenBank accession no. AF343659), IRTA2 (GenBank accession no. AF34364), moFcRH (GenBank accession no. AAG28775) FcγRI (GenBank accession no. AAA35678), FcγRII (Swiss-Prot accession no. P31994), FcγRIII (Swiss-Prot accession no. P08637), FcεRI (Swiss-Prot accession no. P 12319), and FcαRI (Swiss-Prot accession no. P24071).
Figure 4 shows the relative location of the mouse FcR family. Location is indicated in reference to the human FcR related genes at Ch lq21-23 and their orthologous loci on mouse Ch 3 and Ch 1. The microsatellite marker d3Mitl87 is located within moFcRH 1.
Figure 5 shows the multiple alignment comparisons of huFcRHl-5 and mouse FcRHl and 2 amino acid sequences (one-letter code) based on the FcRH3 sequence. Amino acid gaps are indicated by dashes. Consensus ITAM (underlined) and ITIM (italic, underlined) motifs are indicated. Amino acid lengths are indicated in parentheses.
Figure 6 shows domains marked to indicate relatedness of the Ig-like subunits. Ig-like domain homology was determined by generation of a phylogenetic tree using DNAStar software with the CLUSTAL program and assigning arbitrary colors to individual Ig-domains of a given branch. Amino acid identities for full length, extracellular and, cytoplasmic domain comparisons are based on huFcRH3. Closest cytoplasmic relatives are indicated in parentheses. Most identical extracellular comparisons between mouse and human relatives are highlighted in horizontal lines. Comparisons that are not applicable are left blank.
Figure 7 shows the domains of huFcRHl-6, moFcRHl-3 and related proteins. Domains are colored to indicate relatedness of the Ig-like subunits. Ig-like domain homology was determined by generation of a phylogenetic tree using DNAStar software with the CLUSTAL program and assigning arbitrary colors to individual Ig-domains of a given branch. Amino acid identities for full length, extracellular and, cytoplasmic domain comparisons are based on huFcRH3. Closest cytoplasmic relatives are indicated in parentheses. Most identical extracellular comparisons between mouse and human relatives are highlighted in red. Comparisons that are not applicable are left blank.
Figure 8 shows the structural characteristics of the mouse FcRH isoforms.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the
Examples included therein and to the Figures and their previous and following description.
In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:
As used in the specification and the appended claims, the singular forms "a,"
"an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a receptor includes mixtures of various receptors, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.
Ranges may be expressed herein as from "about" one particular value, and/or to
"about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, the phrase "optionally contains two ITAM consensus motifs" means that the two ITAMs may or may not be present and that the description includes both the presence and absence of two ITAM consensus motifs.
As used throughout, by "subject" is meant an individual. Preferably, the subject is a mammal such as a primate, and, more preferably, a human. The term "subject" can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.).
By "isolated nucleic acid" is meant a nucleic acid the structure of which is not identical to that of the naturally occurring nucleic acid or to that of any fragment of the naturally occurring genomic nucleic acid spanning more than three separate genes. The term therefore covers, for example, (a) a DNA which has the sequence of part of the naturally occurring genomic DNA molecules but is not flanked by both of the coding sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as cDNA, a genomic fragment, a fragment produced by polymerase chain reaction, or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. By "label" is meant any detectable tag that can be attached directly (e.g., a fluorescent molecule integrated into a polypeptide or nucleic acid) or indirectly (e.g., by way of binging to a primary antibody a secondary antibody with an integrated fluorscent molecule) to the molecule of interest. A "label" is any tag that can be visualized with imaging methods. The detectable tag can be a radio-opaque substance, radiolabel, a fluorescent label, or a magnetic label. The detectable tag can be selected from the group consisting of gamma-emitters, beta-emitters, and alpha-emitters, gamma- emitters, positron-emitters, X-ray-emitters and fluorescence-emitters suitable for localization. Suitable fluorescent compounds include fluorescein sodium, fluorescein isothiocyanate, phycoerythrin, and Texas Red sulfonyl chloride. See, de Belder & Wik (Preparation and properties of fluorescein-labelled hyaluronate. Carbohydr.
Res.44(2):251-57 (1975). Those skilled in the art will know, or will be able to ascertain with no more than routine experimentation, other fluorescent compounds that are suitable for labeling the molecule. Polypeptides The invention provides members of a cluster of FcR and FcR gene relatives encoded by genes in the human chromosome lq21-23 region, or analogous region in non-human subjects, including for example, chromosome 3 in mouse. A consensus amino acid motif, based on the FcγRI, FcγRU, FcγRUI, and plgR extracellular regions, was used in a GenBank protein database query to identify member of the gene subfamily. Genomic clones were identified that were found to contain FcR relatives and are termed the Fc receptor homolog (FcRH) subfamily: specifically, FcRHl,
FcRH2, FcRPD, and FcRH6. Also, found were mouse Fc receptor homologs designated moFcRl , 2, and 3.
By "homologous" is meant about 25% percent homology or greater. Homology is also characterized by proximity in the location of the genes and by similarities as identified in a composite analysis. As used herein, "percent homology" of two amino acid sequences or of two nucleic acid sequences is determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990)). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410 (1990)). BLAST nucleotide searches are performed with the NBLAST program, score 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches are performed with the XBLAST program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to a reference polypeptide . To obtain gapped alignments for comparison purposes, Gapped Blast is utilized as described in Altschul et al. (Nucl. Acids Res. 25: 3389-3402 (1997)). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used. See http://ww.ncbi.nlm.nih.gov.
By "FcRH" is meant a Type I transmembrane receptor, or an alternatively spliced form thereof, including, for example, a secreted form or a GPI-anchored form, with homology to the classical Fc receptor family. In a preferred embodiment, the FcRH shows homology with the extracellular regions of FcγRI, FcγRII, FcγRIII, or plgR. More specifically, the FcRH shows homology with an amino acid sequence corresponding with the amino terminal sequences of the second Ig domains of the FcγRs and the third Ig domain of plgR or FcγRHl. The FcRH can comprise an extracellular region, a transmembrane region, and a cytoplasmic region. The extracellular region preferably comprises one or more Ig domains, and more preferably less than 9, and even more preferably less than 7 or less than 8 Ig domains. Preferably, the cytoplasmic region comprises more than 107 (including more than 108, 109, 110, 111, 112, 113, 114, 115, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, or 145 amino acids). Alternatively, the cytoplasmic region comprises less than 104 amino acids (including less than 103, 102, 101, 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80). The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ("ITIMs" or "ITAMs). The invention provides isolated FcRHs (e.g., huFcRH 1, 2, 3, and 6, and moFcRHl-3, as described in detail below), as well as fragments and isoforms thereof. The isolated amino acid sequences provided herein optionally are combined with a human signal sequence (e.g., MLPRLLLLICAPLCEP (SEQ ID NO:29), MLLWSLLVIFDAVTEQADS (SEQ ID NO:30), MLLWLLLLILTPGREQS (SEQ ID NO:31), MLLWTAVLLFVPCVG (SEQ ID NO:32)) or a mouse signal sequence (e.g., MPLCLLLLVFAPVGVQS (SEQ ID NO:69), MLPWLLLLICALPCEPA (SEQ ID NO:72), MSGSFSPCVVFTQMWLTLLWTPVN (SEQ ID NO:79)).
In one embodiment, the invention provides huFcRHl and its fragments and isoforms. Thus, in one embodiment of the isolated FcRH, the extracellular region comprises less than four Ig domains. Preferably, the cytoplasmic region comprises less than 104 amino acids and, even more preferably, comprises less than 104 and more than 86 amino acids. In one embodiment, the transmembrane region comprises an acidic amino acid (e.g., glutamate or aspartate). The isolated FcRH of the invention comprises a cytoplasmic region having the amino acid sequence of SEQ ID NO:l, in the presence or absence of conservative amino acid substitutions. Further provided is the isolated FcRH, wherein the extracellular region comprises the amino acid sequence of SEQ ID NO:21, in the presence or absence of conservative amino acid substitutions, and in the presence and absence of a signal sequence. More specifically, the isolated FcRH comprises the amino acid sequence of SEQ ID NO:2, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence. In one embodiment the signal sequence is MLPRLLLLICAPLCEP (SEQ ID NO: 29). In a preferred embodiment, the FcRH of the invention is expressed by myeloid cells (e.g., granulocytes and monocytes). Additional characteristics of the full length FcRHl include a predicted molecular weight of about 46-47 kDaltons; about 425-435 (e.g., 429) amino acids in length with about 35 strongly basic(+) amino acids (K,R), about 45 strongly acidic(-) amino acids (D,E), about 144 hydrophobic amino acids (A,I,L,F,WN), and aboutl27 polar amino acids (Ν,C,Q,S,T,Y); a predicted isolelectric point of about 5-5.5 (e.g., 5.310); and charge of about -9 at PH 7.0. hi another embodiment, the invention provides an isolated FcRH corresponding to huFcRH2, its fragments, or isoforms. Thus, the invention provides a FcRH wherein the cytoplasmic region comprises less than 99 amino acids (e.g., 80, 81, 82, 83, 84, 85,
86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98) and wherein the receptor further comprises an extracellular domain with up to four Ig domains and up to five N-linked glycosylation sites. More specifically, the isolated FcRH has a cytoplasmic region that comprises the amino acid sequence of SEQ ID NO:3, in the presence or absence of conservative amino acid substitutions, or an extracellular region comprising SEQ TD
NO:22, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence. Even more specifically, the isolated FcRH comprises the amino acid sequence of SEQ ID NO:4, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence, h one embodiment, the signal sequence WSLLVTFDANTEQADS (SEQ ID NO: 30). Additional characteristics of the full length FcRHl include a predicted molecular weight of about 50-60 kDaltons; about 495-515 (e.g., 508) amino acids in length with about 44 strongly basic(+) amino acids (K,R), about 49 strongly acidic(-) amino acids (D,E), about 175 hydrophobic amino acids (A,I,L,F,W,V), and about 161 polar amino acids (N,C,Q,S,TN); a predicted isolelectric point of about 6-6.5 (e.g., 6.188); and charge of about -4 atPH 7.0. In another embodiment, the invention provides huFcRH3, its fragments, and isoforms. More specifically, the invention provides an isolated FcRH having a cytoplasmic region that comprises more than 107 amino acids (e.g., 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 212, 122, 123, 124, 125, 126 ,127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 247, 148, 149, 150 amino acids). Optionally, the isolated FcRH has a cytoplasmic region comprising one ITAM and one ITIM. More specifically, the cytoplasmic region comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23, in the presence or absence of conservative amino acid substitutions. In one embodiment, the extracellular domain of the FcRH comprises the amino acid sequence of SEQ ID NO:24, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence. Also provided is an isolated FcRH comprising the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:25, in the presence or absence of one or more amino acid substitutions, and in the presence or absence of a signal sequence. In one embodiment the signal sequence comprises
MLLWLLLLILTPGREQS (SEQ ID NO:31). Additional characteristics of the full length FcRHl include a predicted molecular weight of about 80-90 kDaltons; about
725-740 (e.g., 734) amino acids in length with about 68 strongly basic(+) amino acids (K,R), about 75 strongly acidic(-) amino acids (D,E), about 232 hydrophobic amino acids (A,I,L,F,WN), and about 224 polar amino acids (Ν,C,Q,S,TN); a predicted isolelectric point of about 6.5-7.0 (e.g., 6.852); and charge of about -2 atPH 7.0.
The invention further provides an isolated huFcRHό, its fragments, and isoforms. More specifically, the FcRH comprises a cytoplasmic region having the amino acid sequence of SEQ ID NO:26, in the presence or absence or one or more conservative amino acid substitutions. The extracellular domain comprises the amino acid sequence of SEQ ID NO:27, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence. Also, provided by the invention is a FcRH having the amino acid substitutions of SEQ ID NO:28, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence, hi one embodiment the signal sequence is MLLWTAVLLFVPCVG (SEQ ID NO:32).
The invention further provides a polypeptide comprising the amino acid sequence of SEQ ID NO:l, 21, 2, 3, 22, 4, 5, 23, 24, 6, 25, 26, 27, or 28, in the presence or absence of conservative amino acid substitutions. The invention also provides a polypeptide having at least 80, 85, 90, or 95% homology with SEQ ID NOs: 1, 21, 2, 3, 22, 4, 5, 23, 24, 6, 25, 26, 27, or 28.
The invention further provides an isolated moFcRHl isoform, its fragments, and isoforms. The moFcRHl is an isoform of SEQ ID NO:68. More specifically, the FcRH comprises four Ig domains, optionally having the sequence of SEQ ID NO: 70, in the presence or absence or one or more conservative amino acid substitutions, and in the presence or absence of a signal sequence (e.g., the sequence of SEQ ID NO:71).
The invention further provides an isolated moFcRH2, its fragments, and isoforms. The provided isoforms include one isoform with a transmembrane region and one isoform lacking the transmembrane region. More specifically, the FcRH comprises a cytoplasmic region having the amino acid sequence of SEQ ID NO:76, in the presence or absence or one or more conservative amino acid substitutions. The extracellular domain comprises the amino acid sequence of SEQ ID NO:74, in the presence or absence of conservative amino acid substitutions, and in the presence or absence of a signal sequence. Also, provided by the invention is a FcRH having the amino acid sequence of SEQ ID NO:73, which comprises a transmembrane region, or SEQ ID NO: 77, which lacks the transmembrane region, hi each case, the FcRH sequence can include the presence or absence of conservative amino acid substitutions, and the presence or absence of a signal sequence, h one embodiment the signal sequence is the sequence of SEQ ED NO:72.
The invention also provided a moFcRH3, its fragments and isoforms. The cytoplasmic region can comprise the amino acid sequence of SEQ DD NO:81, in the presence or absence of conservative amino acid substitutions. Optionally, the extracellular domain comprises the amino acid sequence of SEQ ID NO: 80, in the presence or absence of conservative amino acid substitutions or in the presence or absence of a signal sequence (e.g., the sequence of SEQ ID NO:79). The full length sequence optionally has the amin oacid sequence of SEQ ID NO:78, in the presence or absence of conservative amino acid substitutions or in the presence or absence of a signal sequence (e.g., the sequence of SEQ ID NO:79).
Fragments, variants, or isoforms of the FcRHs of the invention are provided. It is understood that these terms include functional variants. Fragments can include the cytoplasmic region, the extracellular region, the transmembrane region or any portion of at least 10 amino acids or any combination of the regions or portions. The variants are produced by making amino acid substitutions, deletions, and insertions, as well as post- translational modifications. Variations in post-translational modifications can include variations in the type or amount of carbohydrate moieties of the protein core or any fragment or derivative thereof. Variations in amino acid sequence may arise naturally as allelic variations (e.g., due to genetic polymoφhism) or may be produced by human intervention (e.g., by mutagenesis of cloned DNA sequences), such as induced point, deletion, insertion and substitution mutants. These modifications can result in changes in the amino acid sequence, provide silent mutations, modify a restriction site, or provide other specific mutations. Amino acid sequence modifications fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl termi al fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site-specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known and include, for example, Ml 3 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues but may include multiple substitutions at different positions; insertions usually will be on the order of about from 1 to 10 amino acid residues but can be more; and deletions will range about from 1 to 30 residues, but can be more. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with Table 1 and are referred to as conservative substitutions.
TABLE 1: Amino Acid Substitutions
Original Residue Exemplary Substitutions
Ala Ser
Arg Lys
Asn Gin
Asp Glu
Cys Ser
Gin Asn
Glu Asp
Gly Pro
His Gin lie Leu; Val
Leu lie; Val
Lys Arg; Gin
Met Leu; lie
Phe Met; Leu; Tyr
Ser Thr
Thr Ser Trp Tyr
Tyr Trp; Phe
Val He; Leu
Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those in Table 1, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions that in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteme or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.
Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Tlir/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteme or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.
Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco pp 79-86 [1983]), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl. Modifications in the FcRH can also include modifications in glycosylation. In all mutational events, it is understood that the controlling aspect of the mutation is the function that the subsequent protein possesses. The preferred mutations are those that do not detectably change the desired function or that increase the desired function.
Nucleic Acids
Also provided is an isolated nucleic acid that encodes the FcRH of the invention. The nucleic acid can be single or double stranded and can be RNA or DNA.
More specifically, the invention provides an isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ID NO:l, SEQ ID NO:21, SEQ ID NO:2. SEQ ID NO: 3, SEQ ID NO:22, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:6, SEQ ID NO:70, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:77, SEQ DD NO:78, SEQ ID NO:80, SEQ ID NO:81, optionally with conservative amino acid substitutions. Optionally the nucleic acid further encodes a signal sequence (e.g., the signal sequences of SEQ ED NO:29, 30, 31, 32, 71, 75, 79). The isolated nucleic acid optionally encodes the sequences with 80, 85, 90, or 95 % identity. More specifically, the invention provides an isolated nucleic acid, comprising a nucleotide sequence of SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO:8, SEQ ID NO:34, SEQ ID NO:9, SEQ ID NO: 14, SEQ DD NO: 10, SEQ DD NO:36, SEQ ID NO:ll, SEQ ID NO:15, SEQ ID NO: 16, SEQ ID NO:12, SEQ ID NO:38, SEQ ED NO:17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:20; SEQ ID NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ DD NO:87, SEQ ID NO:88, SEQ DD NO:89, SEQ DD NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ED NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID
NO: 101, or SEQ ID NO: 102 . Optionally, the isolated nucleic acid can further included bases that encode a signal sequence and thus the nucleotide sequence encoding the extracellular region or full-length huFcRHl, 2, 3, or 6 can optionally further comprise the nucleotide sequence of SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO: 39. Optionally, the isolated nucleic acids for moFcRHs include nucleic acid sequences that encode signal sequences as well, including for example, those portions of nucleic acid sequences SEQ ID NO: 101, SEQ ID NO:97, SEQ ID NO:94, SEQ ID NO:91, SEQ ID NO:88, SEQ ID NO:84. Preferably the nucleic acid that encodes the full length FcRHl includes about 1290 bases. The nucleic acid that encodes the full length FcRH2 includes about 1527 bases, and the nucleic acid that encodes the full length FcRH3 includes about 2205 bases. The invention also provides an isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO:7, SEQ ED NO:13, SEQ ID NO:8, SEQ ED NO:34, SEQ ID NO:9, SEQ ED NO:14, SEQ ED NO:10, SEQ ID NO:36, SEQ ED NO:l 1, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:12, SEQ ID NO:38, SEQ IDNO:17, SEQ ID NO:18, SEQ IDNO:19, and SEQ IDNO:20; SEQ DD NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ED NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ EDNO:100, SEQ IDNO:101, or SEQ IDNO:102, or the complement of either sequence.
Further provided is a single stranded nucleic acid that hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ ED NO:7, SEQ ED NO: 13, SEQ ID NO:8, SEQ ID NO:34, SEQ ID NO:9, SEQ ID NO: 14, SEQ ID NO:10, SEQ ID NO:36, SEQ EDNO:ll, SEQ ED NO:15, SEQ ID NO:16, SEQ EDNO:12, SEQ ED NO:38, SEQ ID NO:17, SEQ DD NO: 18, SEQ ID NO:19, and SEQ ED NO:20; SEQ ID NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ED NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ED NO:98, SEQ ID NO:99, SEQ IDNO:100, SEQ JDNO:101, or SEQ IDNO:102. By "hybridizing under stringent conditions" or "hybridizing under highly stringent conditions" is meant that the hybridizing portion of the hybridizing nucleic acid, typically comprising at least 15 (e.g., 20, 25, 30, or 50 nucleotides), hybridizes to all or a portion of the provided nucleotide sequence under stringent conditions. The term "hybridization" typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide. The hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize. Generally, the hybridizing portion of the hybridizing nucleic acid is at least 80%, for example, at least 90%, 95%, or 98%, identical to the sequence of or a portion of a nucleic acid encoding an FcRH of the invention, or its complement. Hybridizing nucleic acids of the invention can be used, for example, as a cloning probe, a primer (e.g., for PCR), a diagnostic probe, or an antisense probe. Hybridization of the oligonucleotide probe to a nucleic acid sample typically is performed under stringent conditions. Nucleic acid duplex or hybrid stability is expressed as the melting temperature or Tm, which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are related and substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., SSC or SSPE). Assuming that a 1% mismatch results in a 1°C decrease in the Tm, the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequence having >95% identity with the probe are sought, the final wash temperature is decreased by 5 °C). In practice, the change in Tm can be between 0.5 °C and 1.5 °C per 1% mismatch. Stringent conditions involve hybridizing at 68 °C in 5x SSC/5x Denhardt's solution 1.0% SDS, and washing in 0.2x SSC/0.1% SDS at room temperature. Moderately stringent conditions include washing in 3x SSC at 42 °C. The parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, NY) at Unit 2.10. The nucleic acids of the present invention are optionally labeled, directly or indirectly. Such labeled nucleic acids are useful in various diagnostic techniques including for example, in situ hybridization, FISH, in situ PCR, and PRTNS. Both methods involve the preparation of short sequences of singϊe-stranded nucleic acid probes that are complementary to the nucleic acid sequences that encode an FcRH.
See, e.g., M Andreeff and D Pinkel (1999), An Introduction to Flourescent In-Situ
Hybridization: Principles and Clinical Applications, John Wiley & Sons, Ltd; Roche Applied Sciences (2000), Nonradioactive In Situ Hybridization Application Manual;
Roche Applied Sciences (1999), PCR Manual, 2d edition, which are incoφorated in their entirety for methods of using nucleic acids.
Vectors, cells, and methods of using Also provided is an expression vector comprising a nucleic acid of the invention, wherein the nucleic acid is operably linked to an expression control sequence. A wide variety of expression system regulatory sequence combinations may be employed in expressing the disclosed. Such useful regulatory sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenoviras, the lac system, the txp system, the TAC system, the TRC system, the LTR system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (for example, Pho5), the AOX 1 promoter of methylotrophic yeast, the promoters of the yeast a-mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
Such an expression vector can be designed to be expressed by eukaryotic cells or prokaryotic cells. The vectors of the present invention thus provide DNA molecules which are capable of integration into a prokaryotic or eukaryotic chromosome and expression. The inserted genes in viral and retroviral vectors usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements. It has been shown that all specific regulatory elements can be cloned and used to construct expression vectors that are selectively expressed in specific cell types. For example, the glial fibrillary acetic protein (GFAP) promoter has been used to selectively express genes in cells of glial origin. Expression vectors used in eukaryotic host cells (e.g., yeast, fungi, insect, plant, animal, human or nucleated cells) may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contain a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA. The identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constracts. In certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct. The invention further provides transfer vectors, which include any nucleotide construction used to deliver genes into cells (e.g., a plasmid), or as part of a general strategy to deliver genes, e.g., as part of recombinant retrovirus or adenoviras (Ram et al. Cancer Res. 53:83-88, (1993)). As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. In some embodiments the FcRHs are derived from either a virus or a retrovirus. Viral vectors include, for example, Adenoviras, Adeno-associated virus, Heφes virus, Vaccinia virus, Polio virus, ADDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone. Also preferred are any viral families that share the properties of these viruses that make them suitable for use as vectors. Retroviruses include Murine Maloney Leukemia virus, MMLV, and retrovirases that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors, and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells. Adenoviras vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non- dividing cells. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. A preferred embodiment is a viral vector which has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens.
Viral vectors can have higher transaction (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells. Typically, viral vectors contain, nonstractural early genes, stractural late genes, an RNA polymerase HI transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the transcription and replication of the viral genome. When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promotor cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material. The necessary functions of the removed early genes are typically supplied by cell lines that have been engineered to express the gene products of the early genes in trans.
A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral vectors, in general, are described by Verma, I.M., Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is incoφorated by reference herein. Examples of methods for using retroviral vectors for gene therapy are described in U.S. Patent Nos. 4,868,116 and 4,980,286; PCT applications WO 90/02806 and WO 89/07136; and Mulligan, (Science 260:926-932 (1993)); the teachings of which are incoφorated herein by reference. A retrovirus is essentially a package which has packed into it nucleic acid cargo. The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules that are needed in cis, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are involved in the making of the protein coat. It is the gag, pol, and env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell. Retrovirus vectors typically contain a packaging signal for incoφoration into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome. The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert. Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line that has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.
The construction of replication-defective adenoviruses has been described (Berkner et al., J. Virology 61:1213-1220 (1987); Massie et al., Mol. Cell. Biol. 6:2872- 2883 (1986); Haj-Ahmad et al., J. Virology 57:267-274 (1986); Davidson et al., J. Virology 61:1226-1239 (1987); Zhang, Generation and identification of recombinant adenoviras by liposome-mediated transfection and PCR analysis, BioTechniques 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, J. Clin. Invest. 92:1580-1586 (1993); Kirshenbaum, J. Clin. Invest. 92:381-387 (1993);
Roessler, J. Clin. Invest. 92:1085-1092 (1993); Moullier, Nature Genetics 4:154-159 (1993); La Salle, Science 259:988-990 (1993); Gomez-Foix, J. Biol. Chem. 267:25129-25134 (1992); Rich, Human Gene Therapy 4:461-476 (1993); Zabner, Nature Genetics 6:75-83 (1994); Guzman, Circulation Research 73:1201-1207 (1993); Bout, Human Gene Therapy 5:3-10 (1994); Zabner, Cell 75:207-216 (1993); Caillaud, Eur. J. Neuroscience 5:1287-1291 (1993); and Ragot, J. Gen. Virology 74:501-507 (1993)). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenoviras (Chardonnet and Dales, Virology 40:462-477 (1970); Brown and Burlingham, J. Virology 12:386-396 (1973); Svensson and Persson, J. Virology 55:442-449 (1985); Seth, et al., J. Virol. 51:650-655 (1984); Seth, et al., Mol. Cell. Biol. 4:1528-1533 (1984); Varga et al., J. Virology 65:6061-6070 (1991); Wickham et al., Cell 73:309-319 (1993)).
A viral vector can be one based on an adenoviras which has had the El gene removed and these virons are generated in a cell line such as the human 293 cell line, hi another preferred embodiment both the El and E3 genes are removed from the adenoviras genome.
Another type of viral vector is based on an adeno-associated virus (AAV). This defective parvoviras is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type of vector is the P4.1 C vector produced by Avigen, San Francisco, CA, which can contain the heφes simplex virus thymidine kinase gene, HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.
In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvoviras.
Typically the AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector. The AAV ITRs, or modifications thereof, confer infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression. United States Patent No. 6,261,834 is herein incoφroated by reference for material related to the AAV vector. Molecular genetic experiments with large human heφesviruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with heφesvirases (Sun et al., Nature genetics 8: 33-41, 1994; Cotter and Robertson, Curr Opin Mol Ther 5: 633-644, 1999). These large DNA viruses (heφes simplex viras (HSV) and Epstein-Barr viras (EBV), have the potential to deliver fragments of human heterologous DNA > 150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B- cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable The maintenance of these episomes requires a specific EBV nuclear protein, EBNA1 , constitutively expressed during infection with EBV.
Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently in vitro. Heφesviras amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes. Other useful systems include, for example, replicating and host-restricted non-replicating vaccinia viras vectors.
The invention also provides an isolated cell comprising a vector of the invention. The isolated cell can be either a eukaryotic or prokaryotic cell, such as strains of E. coli, Pseudomonas, Bacillus , Streptomyces; fungi such as yeasts (Saccharomyces , and methylotrophic yeast such as Pichia, Candida, Hansenula, and Torulopsis); and animal cells, such as CHO, Rl.l, B-W and LM cells, African Green Monkey kidney cells (for example, COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (for example, Sf9), and human cells and plant cells in tissue culture.
Also provided is a method of making a FcRH, or a fragment or variant thereof comprising culturing a cell comprising a vector of the invention under conditions permitting expression of the FcRH. The method comprises culturing a cell comprising an exogeneous nucleic acid that encodes the FcRH, fragment, or variant, wherein the exogeneous nucleic acid is operably linked to an expression control sequence, and wherein the culture conditions permit expression of the FcRH, fragment, or variant under the control of the expression control sequence; harvesting the medium from the cultured cells, and isolating the FcRH, fragment, or varinat from the cell or culture medium. Optionally the exogenous nucleic acid is the nucleotide sequence of SEQ ED NO:7, SEQ ID NO: 13, SEQ ED NO:8, SEQ ID NO:34, SEQ ID NO:9, SEQ ID NO: 14, SEQ ID NO:10, SEQ ID NO:36, SEQ ID NO:ll, SEQ ED NO:15, SEQ ID NO:16, SEQ ID NO:12, SEQ ID NO:38, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and SEQ
DD NO:20; SEQ ID NO:40, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:87, SEQ ID
NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ED NO:91, SEQ ID NO:92, SEQ ID
NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ED NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ED NO:99, SEQ ID NO:100, SEQ ID NO:101, or SEQ ID NO:102 or a combination thereof. Optionally, the exogenous nucleic acid further comprises a nucleotide sequence that encodes a signal sequence. In the recombinant methods, the cell can be any known host cell, including for example, a prokaryotic or eukaryotic cell.
The nucleic acids that are delivered to cells, generally in a plasmid or other vector, typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product.
Those skilled in the art of molecular biology will understand that a wide variety of expression systems may be used to produce recombinant FcRH polypeptides (as well as fragments, fusion proteins, and amino acid sequence variants with therapeutic activity) for use in the methods of the invention. Thus, FcRH may be produced using prokaryotic host cells (e.g., Escherichia coli) or eukaryotic host cells (e.g., Saccharomyces cerevisiae, insect cells such as Sf9 cells, or mammalian cells such as CHO cells, COS-1, NTH 3T3, or HeLa cells). These cells are commercially available from, for example, the American Type Culture Collection, RockviUe, MD (see also F. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1998). The method of transformation and the choice of expression vector will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al., supra, and expression vectors may be chosen from the numerous examples known in the art.
A nucleic acid sequence encoding an FcRH is introduced into a plasmid or other vector, which is then used to transform living cells. Constracts in which a cDNA containing the entire FcRH coding sequence, a fragment of the FcRH coding sequence, amino acid variations of the FcRH coding sequence, or fusion proteins of the aforementioned, inserted in the correct orientation into an expression plasmid, may be used for protein expression. In some cases, for example, it may be desirable to express the FcRH coding sequence under the control of an inducible or tissue-specific promoter. Eukaryotic expression systems permit appropriate post-translational modifications to expressed proteins. Thus, eukaryotic, and more preferably mammalian expression systems, allow glycosylations patterns comparable to naturally expressed FcRH. Transient transfection of a eukaryotic expression plasmid allows the transient production of FcRH by a transfected host cell. FcRH may also be produced by a stably- transfected mammalian cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public (e.g., see Pouwels et al., Cloning Vectors: A Laboratory Manual, 1985, Supp. 1987), as are methods for constructing such cell lines (see e.g., F. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1998). Another preferred eukaryotic expression system is the baculovirus system using, for example, the vector pBacPAK9, which is available from Clontech (Palo Alto, CA). If desired, this system may be used in conjunction with other protein expression techniques, for example, the myc tag approach described by Evan et al. (Mol. Cell Biol. 5:3610-3616, 1985) or analogous tagging approaches, e.g., using a hemagluttinin (HA) tag.
Once the recombinant protein is expressed, it can be isolated from the expressing cells by cell lysis followed by protein purification techniques such as affinity chromatography. In this example, an antibody that specifically binds to FcRH, which may be produced by methods that are well-known in the art, can be attached to a column and used to isolate FcRH. Once isolated, the recombinant protein can, if desired, be purified further, e.g., by high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, Work and Burdon, Eds., Elsevier, 1980).
Antibodies
The invention also provides a purified antibody or immunologic fragment thereof, wherein the antibody or fragment thereof selectively binds to an FcRH. As used herein, the term "antibody" encompasses, but is not limited to, whole immunoglobulin (i.e., an intact antibody) of any class. Native antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V(H)) followed by a number of constant domains. Each light chain has a variable domain at one end (V( )) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (k) and lambda (1), based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these maybe further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA- 2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
The term "variable" is used herein to describe certain portions of the variable domains that differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a b-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the b-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies (see Kabat E. A. et al., "Sequences of Proteins of Immunological Interest" National Institutes of Health, Bethesda, Md. (1987)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody- dependent cellular toxicity. The term "antibody or fragments thereof can also encompass chimeric antibodies and hybrid antibodies, with dual or multiple antigen or epitope specificities, and fragments, such as F(ab')2, Fab', Fab and the like, including hybrid fragments.
Thus, fragments of the antibodies that retain the ability to bind their specific antigens are provided. For example, fragments of antibodies which maintain FcRH binding activity are included within the meaning of the term "antibody or fragment thereof." Such antibodies and fragments can be made by techniques known in the art and can be screened for specificity and activity according to the methods set forth in the Examples and in general methods for producing antibodies and screening antibodies for specificity and activity (See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).
Also included within the meaning of "antibody or fragments thereof are conjugates of antibody fragments and antigen binding proteins (single chain antibodies) as described, for example, in U.S. Pat. No. 4,704,692, the contents of which are hereby incoφorated by reference .
In one embodiment, the antibody is a monoclonal antibody. The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
Monoclonal antibodies of the invention may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975) or Harlow and Lane, Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988). In a hybridoma method, a mouse or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. Preferably, the immunizing agent comprises an FcRH. Traditionally, the generation of monoclonal antibodies has depended on the availability of purified protein or peptides for use as the immunogen. More recently DNA based immunizations have shown promise as a way to elicit strong immune responses and generate monoclonal antibodies, hi this approach, DNA-based immunization can be used, wherein DNA encoding a portion of FcRH, preferably the N- or C- terminal region, is injected into the host animal according to methods known in the art.
Generally, either peripheral blood lymphocytes ("PBLs") are used in methods of producing monoclonal antibodies if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, "Monoclonal Antibodies: Principles and Practice" Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, including myeloma cells of rodent, bovine, equine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif, and the American Type Culture Collection, RockviUe, Md. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., "Monoclonal Antibody Production Techniques and Applications" Marcel Dekker, Inc., New York, (1987) pp. 51-63). The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against an FcRH. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art, and are described further in Harlow and Lane "Antibodies, A Laboratory Manual" Cold Spring Harbor Publications, New York, (1988).
After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution or FACS sorting procedures and grown by standard methods. Suitable culture media for this puφose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.
The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, plasmacytoma cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No.4,816,567) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for FcRH and another antigen-combining site having specificity for a different antigen.
In vitro methods are also suitable for preparing monovalent antibodies.
Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994, U.S. Pat. No. 4,342,566, and Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, (1988). Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment, called the F(ab')2 fragment, that has two antigen combining sites and is still capable of cross-linking antigen.
The Fab fragments produced in the antibody digestion also contain the constant domains of the light chain and the first constant domain of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain domain including one or more cysteines from the antibody hinge region. The F(ab') fragment is a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge at the hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. Antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
An isolated immunogenically specific epitope or fragment of the antibody is also provided. A specific immunogenic epitope of the antibody can be isolated from the whole antibody by chemical or mechanical disruption of the molecule. The purified fragments thus obtained can be tested to determine their immunogenicity and specificity by the methods taught herein. Immunoreactive epitopes of the antibody can also be synthesized directly. An immunoreactive fragment is defined as an amino acid sequence of at least about two to five consecutive amino acids derived from the antibody amino acid sequence. One method of producing proteins comprising the antibodies of the present invention is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyl- oxycarbonyl) or Boc (tert -butyloxycarbonoyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the antibody of the present invention, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of an antibody can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group that is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof. (Grant GA (1992) Synthetic Peptides: A User Guide. W.H. Freeman and Co., NN. (1992); Bodansky M and Trost B., Ed. (1993) Principles of Peptide Synthesis. Springer- Verlag hie, ΝY). Alternatively, the peptide or polypeptide can by independently synthesized in vivo as described above. Once isolated, these independent peptides or polypeptides may be linked to form an antibody or fragment thereof via similar peptide condensation reactions. For example, enzymatic ligation of cloned or synthetic peptide segments can allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L et al., Biochemistry, 30:4151 (1991)). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson et al.
Synthesis of Proteins by Native Chemical Ligation. Science, 266:776-779 (1994)). The first step is the chemoselective reaction of an unprotected synthetic peptide-α-thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site. Application of this native chemical ligation method to the total synthesis of a protein molecule is illustrated by the preparation of human interleukin 8 (IL-8) (Baggiolini M et al. (1992) FEBS Lett. 307:97-101; Clark-Lewis I et al., J.Biol.Chem., 269:16075 (1994); Clark-Lewis I et al.
Biochemistry, 30:3128 (1991); Rajarathnam K et al. Biochemistry 33:6623-30 (1994)).
Alternatively, unprotected peptide segments can be chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (non-peptide) bond (Schnolzer, M et al. Science, 256:221 (1992)). This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton RC et al. Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257-267
(1992)). The invention also provides fragments of antibodies that have bioactivity. The polypeptide fragments of the present invention can be recombinant proteins obtained by cloning nucleic acids encoding the polypeptide in an expression system capable of producing the polypeptide fragments thereof, such as an adenoviras or baculoviras expression system. For example, one can determine the active domain of an antibody from a specific hybridoma that can cause a biological effect associated with the interaction of the antibody with FcRH. For example, amino acids found to not contribute to either the activity or the binding specificity or affinity of the antibody can be deleted without a loss in the respective activity.
For example, amino or carboxy-terminal amino acids can be sequentially removed from either the native or the modified non-immunoglobulin molecule or the immunoglobulin molecule and the respective activity assayed in one of many available assays, h another example, a fragment of an antibody can comprise a modified antibody wherein at least one amino acid has been substituted for the naturally occurring amino acid at a specific position, and a portion of either amino terminal or carboxy terminal amino acids, or even an internal region of the antibody, has been replaced with a polypeptide fragment or other moiety, such as biotin, which can facilitate in the purification of the modified antibody. For example, a modified antibody can be fused to a maltose binding protein, through either peptide chemistry of cloning the respective nucleic acids encoding the two polypeptide fragments into an expression vector such that the expression of the coding region results in a hybrid polypeptide. The hybrid polypeptide can be affinity purified by passing it over an amylose affinity column, and the modified antibody receptor can then be separated from the maltose binding region by cleaving the hybrid polypeptide with the specific protease factor Xa. (See, for example, New England Biolabs Product Catalog, 1996, pg. 164.).
Similar purification procedures are available for isolating hybrid proteins from eukaryotic cells as well.
The fragments, whether attached to other sequences, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove or add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antigen. (Zoller MJ et al. Nucl. Acids Res. 10:6487-500 (1982).
As used herein, the phrase "specific binding" or "selective binding" refers to a binding reaction which is determinative of the presence of the FcRH in a heterogeneous population of proteins and other biologies. Thus, under designated conditions, the antibodies or fragments thereof of the present invention bind to a particular FcRH (e.g, human FcRH 1 or any variant thereof), fragment, or variant thereof and do not bind in a significant amount to other proteins (e.g, human FcRH 2, 3, 4, 5, or 6), present in the subject. The absence of binding in the present invention is concisderd to be binding that is less than 1.5 times background (i.e., the level of non-specific binding or slightly above non-specific binding levels),
Selective binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein, variant, or fragment. In one embodiment the purified antibody selectively binds to the FcRH comprising a cytoplasmic region with more than 107 or less than 104 amino acids, a transmembrane region, and an extracellular region. More specifically, the antibody in alternative embodiments selectively binds FcRHl but not FcRH2-6; selectively binds FcRH2 but not 1 or 3-6; selectively binds FcRH3 but not FcRHl-2 or 4-6; selectively binds FcRH6 but not 1-5. Thus, as one embodiment, the antibody selectively binds a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, 21, or 2, or a subset thereof, but not to polypeptides comprising the amino acid of SEQ ID NO:3, 22, 4, 5, 23, 24, 6, 25,
26, 27, 28, or a subset thereof. In another embodiment the purified antibody binds to the FcRH comprising the amino acid sequence of SEQ ID NO:3, 22, or 4, but not to the FcRH comprising the amino acid of SEQ ID NO: 1 , 21 , 2, 5, 23, 24, 6, 25, 26, 27, or 28.
In yet another embodiment, the purified antibody that binds to the FcRH comprising the amino acid sequence of SEQ ID NO:5, 23, 24, or 6, but not to the FcRH comprising the amino acid of SEQ ID NO:l, 21, 2, 3, 22, 4, 26, 27, 28. Similarly, the antibodies of the present invention may bind only moFcRHl , but not moFcRH 2 or moFcRH3 ; may bind only FcRH2 and not FcRHl or FcRH3, and may bind only FcRH3 and not FcRHl orFcRH2.
In certain embodiments, the antibody binds the extracellular region of one or more FcRHs and in other embodiments the antibody binds the cytoplasmic region of one or more FcRHs. In other embodiments the antibody may selectively bind one isoform of a FcRH. For example, the antibody may bind a polypeptide having the amino acid sequence of SEQ ED NO:23 but not the SEQ ED NO:24 or vice versa. Furthermore, the antibody can bind to moFcRHl having the amino acid sequence of SEQ ID NO:70, but not to a moFcRHl having amino acid sequence of SEQ ID NO:68. The antibody may selectively bind a moFcRH2 with a transmembrane region (e.g, having amino acid sequence of SEQ ED NO:73), but not bind to a moFcRH2 lacking a transmembrane region (e.g, having the amino acid sequence of 77). Optionally the antibody of the invention can selectively bind moFcRH but not human, or vice versa.
A variety of immunoassay formats may be used to select antibodies that selectively bind with a particular protein, variant, or fragment. For example, solid- phase ELISA immunoassays are routinely used to select antibodies selectively immunoreactive with a protein, variant, or fragment thereof. See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988), for a description of immunoassay formats and conditions that could be used to determine selective binding. The binding affinity of a monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem, 107:220 (1980).
The invention also provides an antibody reagent kit comprising the antibody or fragment thereof of the invention and reagents for detecting binding of the antibody or fragment thereof to a ligand. The kit can further comprise containers containing the antibody or fragment thereof of the invention and containers containing the reagents.
Preferably the ligand is a FcRH, variant, or fragment thereof. Particularly, the kit can detect the presence of one or more FcRHs specifically reactive with the antibody or an immunoreactive fragment thereof. The kit can include an antibody bound to a substrate, a secondary antibody reactive with the antigen and a reagent for detecting a reaction of the secondary antibody with the antigen. Such a kit can be an ELISA kit and can comprise the substrate, primary and secondary antibodies when appropriate, and any other necessary reagents such as detectable moieties, enzyme substrates and color reagents as described above. The diagnostic kit can, alternatively, be an immunoblot kit generally comprising the components and reagents described herein. Alternatively, the kit could be a radioimmunoassay kit, a Western blot assay kit, an immunohistological assay kit, an immunocytochemical assay kit, a dot blot assay kit, a fluorescence polarization assay kit, a scintillation proximity assay kit, a homogeneous time resolved fluorescence assay kit, or a BIAcore analysis kit.
As used throughout, methods of detecting an FcRH or antigen antibody complexes, including complexes comprising an FcRH and optionally the antibody of the present invention, can comprise an ELISA (competition or sandwich), a radioimmunoassay, a Western blot assay, an immunohistological assay, an immunocytochemical assay, a dot blot assay, a fluorescence polarization assay (Jolley (1981); Jiskoot et al (1991); Seethala et al. (1998); Bicamumpaka et al. (1998)), a scintillation proximity assay (Amersham Life Science (1995) Proximity News. Issue 17; Amersham Life Science (1995) Proximity News. Issue 18; Park et al. (1999)), a homogeneous time-resolved fluorescence assay (Park et al. (1999); Stenroos et al. (1988); Morrison, 1988)), or a BIAcore analysis Fagerstam et al. (1992)
Chromatography 597:397-410. Preferably, the antigen/antibody complex is detectably tagged either directly or indirectly. Any desired tag can be utilized, such as a fluorescent tag, a radiolabel, a magnetic tag, or an enzymatic reaction product.
Optionally, the antibody or fragment is a humanized antibody or a fully human antibody. For example, the antibodies can also be generated in other species and
"humanized" for administration to humans. Alternatively, fully human antibodies can also be made by immunizing a mice or other species capable of making a fully human antibody (e.g, mice genetically modified to produce human antibodies), screening clones that bind FcRH. See, e.g, Lonberg and Huszar (1995) Human antibodies from transgenic mice, Int. Rev. Immunol. 13:65-93, which is incoφorated herein by reference in its entirety for methods of producing fully human antibodies. As used herein, the term "humanized" and "fully human" in relation to antibodies, relate to any antibody which is expected to elicit a therapeutically tolerable weak immunogenic response in a human subject.
Humanized forms of non-human (e.g, murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' ,
F(ab')2, or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, hi general, the humanized antibody will comprise substantially all or at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al. Nature, 321:522-525 (1986); Riechmann et al. Nature, 332:323-327 (1988); and Presta, Curr. Op. Struct. Biol, 2:593-596 (1992)).
Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al. Nature, 321:522-525 (1986); Riechmann et al. Nature, 332:323-327 (1988); Verhoeyen et al. Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important in order to reduce antigenicity. According to the "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al, J. Immunol, 151:2296 (1993) and Chothia et al, J. Mol. Biol, 196:901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al, Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al, J. Immunol, 151:2623 (1993)).
It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three- dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding (see, WO 94/04679 published 3 Mar. 1994). Transgenic animals (e.g, mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g, Jakobovits et al, Proc. Natl. Acad. Sci. USA, 90:2551-255
(1993); Jakobovits et al. Nature, 362:255-258 (1993); Bruggemann et al. Year in hnmuno, 7:33 (1993)). Human antibodies can also be produced in phage display libraries (Hoogenboom et al, J. Mol. Biol, 227:381 (1991); Marks et al, J. Mol. Biol, 222:581 (1991)). The techniques of Cote et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al, J. Immunol, 147(1):86- 95 (1991)).
In one embodiment, the antibody or fragment thereof is a single chain antibody. In another embodiment, the antibody or fragment is labeled. Optionally the antibody or fragment is conjugated or fused with a toxin or fragment thereof. Examples of the toxin or toxin moiety include diphtheria, ricin, and modifications thereof.
Diagnosis and Treatment
The invention provides uses of the reagents described herein in in vitro and in vivo methods of diagnosing and treating a malignancy of hematopoietic cell lineage or an autoimmune disease in a subject. The reagents of the present invention are also useful in screening for disease manifestations. Such screening may be useful even before the onset of other clinical symptoms and could be used to screening subjects at risk for disease, so that prophylactic treatment can be started before the manifestation of other signs or symptoms.
By "malignancy" is meant a tumor or neoplasm whose cells possess one or more nuclear or cytoplasmic abnormalities, including, for example, high nuclear to cytoplasmic ratio, prominent nucleolar/nucleoli variations, variations in nuclear size, abnormal mitotic figures, or multinucleation. "Malignancies of hematopoietic cell lineage" include, but are not limited to, myelomas, leukemias, lymphomas (Hodgkin's and non-Hodgkin's forms), T-cell malignancies, B-cell malignancies, and lymphosarcomas or other malignancies described in the REAL classification system or the World Health Organization Classification of Hematologic Malignancies. It should be noted that the absence or presence of specific FcRHs can be diagnostic for a particular malignancy of hematopoietic cell linage or can be diagnostic for a particular form of a malignancy (e.g, a specific form of leukemia).
By "inflammatory and autoimmune diseases" illustratively including systemic lupus erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-versus-host disease, Sjόgren's syndrome, pernicious anemia, Addison disease, scleroderma, Goodpasture's syndrome, Crohn's disease, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Basedow's disease, thrombopenia puφura, insulin-dependent diabetes mellitus, allergy; asthma, atopic disease; arteriosclerosis; myocarditis; cardiomyopathy; glomemlar nephritis; hypoplastic anemia; rejection after organ transplantation and numerous malignancies of lung, prostate, liver, ovary, colon, cervix, lymphatic and breast tissues.
Specifically, the diagnostic methods comprise the steps of contacting a biological sample of the subject with an antibody or nucleic acid of the invention under conditions that allow the antibody to bind to cells of hematopoietic cell lineage or allow the nucleic acid to hybridize, preferably under stringent conditions, with nucleic acids of the biological sample; and detecting the amount or pattern of binding. Changes in the amount or pattern of binding as compared to binding in a control sample indicate a malignancy or an inflammatory or autoimmune disease.
In various embodiments, the antibody used in the diagnostic method can selectively bind with an FcRH having the amino acid sequence of SEQ ED NO: 1, 21, 2, 3, 22, 4, 5, 24, or 6.
The detecting step of the diagnostic method can be selected from methods routine in the art. For example, the detection step can be performed in vivo using a noninvasive medical technique such as radiography, fluoroscopy, sonography, imaging techniques such as magnetic resonance imaging, and the like. In vitro detection methods can be used to detect bound antibody or fragment thereof in an ELISA, RIA, immunohistochemically, FACS, IHC, FISH, or similar assays.
As used throughout, "biological sample" refers to a sample from any organism. The sample can be, but is not limited to, peripheral blood, plasma, urine, saliva, gastric secretion, feces, bone marrow specimens, primary tumors, embedded tissue sections, frozen tissue sections, cell preparations, cytological preparations, exfoliate samples
(e.g, sputum), fine needle aspirations, amnion cells, fresh tissue, dry tissue, and cultured cells or tissue. It is further contemplated that the biological sample of this invention can also be whole cells or cell organelles (e.g, nuclei). The sample can be unfixed or fixed according to standard protocols widely available in the art and can also be embedded in a suitable medium for preparation of the sample. For example, the sample can be embedded in paraffin or other suitable medium (e.g, epoxy or acrylamide) to facilitate preparation of the biological specimen for the detection methods of this invention.
The invention also provides a method of treating a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject, comprising contacting the subject's malignant cells or inflammatory cells with a therapeutically effective amount of a reagent (e.g, an antibody or nucleic acid) or a therapeutic composition of a reagent of the invention. The contacting step can occur by administration of the reagent or composition using any number of means available in the art. Typically, the reagent or composition is administered to the subject transdermally (e.g, by a transdermal patch or a topically applied cream, ointment, or the like), orally, subcutaneously, intrapulmonaryily, transmucosally, intraperitoneally, intrauterinely, sublingually, intrathecally, intramuscularly, intraarticularly, etc. using conventional methods, i addition, the reagent or composition can be administered via injectable depot routes such as by using 1-, 3-, or 6-month depot injectable or biodegrable materials and methods.
Regardless of the route of administration, the amount of the reagent administered or the schedule for administration will vary among individuals based on age, size, weight, condition to be treated, mode of administration, and the severity of the condition. One skilled in the art will realize that dosages are best optimized by the practicing physician and methods for determining dosage are described, for example in Remington's Pharmaceutical Science, latest edition. Guidance in selecting appropriate doses for antibodies is found in the literature on therapeutic uses of antibodies, e.g.
Handbook of Monoclonal Antibodies, Ferrone et al, eds, Noges Publications, Park Ridge, NJ, (1985) ch. 22 and pp. 303-357; Smith et al. Antibodies in Human Diagnosis and Therapy, Haber et al, eds. Raven Press, New York (1977) pp. 365-389. A typical dose of the antibody used alone might range from about 1 μg/kg to up to 100 mg/kg of body weight or more per day, and preferably 1 μg/kg to up to 1 mg/kg, depending on the factors mentioned above. An intravenous injection of the antibody or fragment thereof, for example, could be lOng-lg of antibody or fragment thereof, and preferably lOng-lmg depending on the factors mentioned above. For local injection, a typical quantity of antibody ranges from lpg tolmg . Preferably, the local injection would be at an antibody concentration of 1-100 μg/ml, and preferably 1-20 μg/ml.
The nucleic acids of the invention can delivered to cells in a variety of ways.
For example, if the nucleic acid of this invention is delivered to the cells of a subject in an adenoviras vector, the dosage for administration of adenoviras to humans can range from about 10^ to 10-^ plaque forming units (pfu) per injection, but can be as high as lθl2 pfu per injection. Ideally, a subject will receive a single injection. If additional injections are necessary, they can be repeated at six month intervals for an indefinite period and/or until the efficacy of the treatment has been established. As set forth herein, the efficacy of treatment can be determined by evaluating the clinical parameters.
The exact amount of the nucleic acid or vector required will vary as described above. Thus, it is not possible to specify an exact amount for every nucleic acid or vector. An appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
The invention further provides a therapeutic composition of the reagent of the invention. Such a composition typically contains from about 0.1 to 90% by weight (such as 1 to 20% or 1 to 10%) of a therapeutic agent of the invention in a pharmaceutically acceptable carrier. Solid formulations of the compositions for oral administration may contain suitable carriers or excipients, such as com starch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodium chloride, or alginic acid. Disintegrators that can be used include, without limitation, microcrystalline cellulose, corn starch, sodium starch, glycolate, and alginic acid. Tablet binders that may be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolindone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch, and ethylcellulose. Lubricants that may be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica. Liquid formulations for oral administration prepared in water or other aqueous vehicles may contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations may also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents. Various liquid and powder formulations can be prepared by conventional methods for inhalation into the lungs of the mammal to be treated.
Injectable formulations of the compositions may contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like). For intravenous injections, water soluble version of the compounds may be administered by the drip method, whereby a pharmaceutical formulation containing the antifungal agent and a physiologically acceptable excipient is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. Intramuscular preparations, e.g, a sterile formulation of a suitable soluble salt form of the compounds, can be dissolved and administered in a pharmaceutical excipient such as water-for- injection, 0.9% saline, or 5% glucose solution. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (e.g, ethy; oleate).
A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, e.g, 5 to 10%, in a carrier such as a pharmaceutical cream base. Various formulations for topical use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles. The optimal percentage of the therapeutic agent in each pharmaceutical formulation varies according to the formulation itself and the therapeutic effect desired in the specific pathologies and correlated therapeutic regimens.
The effectiveness of the method of treatment can be assessed by monitoring the patient for known signs or symptoms of the conditions being treated. For example, in the treatment of a malignancy of hematopoietic cell lineage, the reduction or stabilization of the number of abnormally proliferative cells would indicate successful treatment, i the treatment of arthritis, for example, a reduction in the amount of joint inflammation would indicate successful treatment. Thus, by"therapeutically effective" is meant an amount that provides the desired treatment effect. The invention further provides a method of modulating a humoral immune response in a subject, comprising administering to the subject an isolated FcRH, an antibody, or nucleic acid of the invention. By "modulation" is meant either up- regulating or down-regulating. Thus, in the case of an allergic response, one skilled in the art would choose to down-regulate the humoral immune response. In the case of exposure of a subject to an infectious agent (e.g, a viral or bacterial agent), one skilled in the art would choose to upregulate the humoral antibody response.
Experimental
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g, amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.
EXAMPLE 1 Identification of FcRHl. FcRH2. and FcRH3
In order to isolation of FcRH cDNA Clones, rapid amplification of cDNA ends (RACE)-PCR was performed by using a Marathon-Ready human lymph node cDNA library (CLONTECH). Gene-specific primers were as follows: FcRH3, forward 5'- TGAGTCTCAGGGTCACAGTTCCG-3' (SEQ ID NO:41) and reverse 5'- GCTCTTGAACTTGGATATTTAGGGGT-3' (SEQ DD NO:42); FcRH2, forward 5'-CCAGTGTATGTCAATGTGGGCTCTG-3' (SEQ ID NO:43) and reverse 5'- CGTTGAAAGAGCTCTTGGACTTTTATC-3' (SEQ ID NO:44); and FcRHl, forward 5'-GCCTCAAAAGAAAAATAGGAAGACGTT-3' (SEQ ID NO:45) and reverse 5'- AAGCTCACATCAGCGACAGGGAC-3' (SEQ ID NO:46). RACE products were subjected to a second round of nested PCR and visualized by agarose gel electrophoresis and ethidium bromide staining.
Primers used in end-to-end amplification to generate full-length cDNAs were as follows: FcRH3, forward 5*-TCTTGGAGATAAGTCGGGCTTT-3' (SEQ ID NO:47) and reverse 5'-ATCCTGCAGCCCAGCCTCGTAGGAG-3' (SEQ DD NO:48); FcRH2, forward 5'-GGTCCTCATGCTGCTGTGGTCATT-3' (SEQ ID NO:49)and reverse 5'-
GCTGTTGATCTTCCCTTCTGATTC-3' (SEQ ID NO:50); and FcRHl, forward 5'-
ATGCTGCCGAGGCTGTTGCTGTTG3' (SEQ ID NO: 51) and reverse 5*- CATAGCATCTTCATAGTCCACATC-3' (SEQ ID NO:52). Each amplification reaction underwent initial denaturation of 94°C for 30 s followed by 30 cycles of denaturation at 94°C for 5 s and annealing at 68°C for 4 min, and final extension at 72°C for 6 min.
PCR products were ligated into the pCR2.1 TOPO T/A vector (Invitrogen). Inserts were DNA-sequenced on both strands by the dideoxy chain termination method using Thermo Sequenase (Amersham Pharmacia) and an automated sequencer (Li-Cor, Lincoln, NE). Nucleotide and amino acid sequence alignment was analyzed with a DNASTAR (Madison, WI) software package, and homology searches were performed by using BLAST (Altschul, S. F. et al. (1990) J. Mol. Biol. 215, 403-410). RNA blot analysis was subsequently performed. Northern blots (CLONTECH) were hybridized with 32P-dCTP-labeled probes: a 528-bp EcoRI fragment corresponding to the 5' untranslated (UT)-ECl regions of the FcRH3 cDNA, a 200-bp PCR product corresponding to a portion of the 3' UT region of the FcRH2 cDNA, and a 257-bp PCR product corresponding to a portion of the 3' UT region of the FcRHl cDNA. Membranes were hybridized for 1 h at 65°C, washed, and exposed to x-ray film (Kubagawa, H. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 5261-5266).
Reverse transcription (RT)-PCR was performed. Human tonsillar cells, obtained with Institutional Review Board approval, were separated into CD 19+ and CD 19 subpopulations by magnetic cell sorting (Miltenyi Biotec, Auburn, CA). Viable CD19+ cells were stained with FITC-labeled anti-CD38 (hnmunotech, Westbrook, ME) and phycoerythrin-labeled anti-IgD mAbs (Southern Biotechnology Associates) before sorting cells with a FACStarPlus instrument (Becton Dickinson) into Trizol reagent (Life Technologies, Grand Island, NY) for RNA isolation. Total cellular RNA was primed with random hexamers and oligo(dT) primers and reverse-transcribed with Superscript II (Life Technologies) into single-stranded cDNA. RT-PCR was performed by using RNA from tonsillar B cells and cell lines, with GEBCO/BRL Taq polymerase (Life Technologies). The following gene-specific primer pairs were used in the RT- PCR analysis of FcRHl -5 expresion in cell lines and tonsillar B cell subpopulations: FcRHl forward, 5'-CTC AAC TTC ACA GTG CCT ACT GGG-3' (SEQ ID NO:53) and reverse, 5'-TCC TGC AGA GTC ACT AAC CTT GAG-3' (SEQ ID NO:54); FcRH2 forward, 5'-CCA GTG TAT GTC AAT GTG GGC TCT G (SEQ ED NO:55) and reverse, 5'-CAT TCT TCC CTC AAA TCT TTA CAC-3' (SEQ DD NO:56); FcRH3 forward, 5'-CAG CAC GTG GAT TCG AGT CAC-3' (SEQ ID NO:57) and reverse, 5'- CAG ATC TGG GAA TAA ATC GGG TTG-3' (SEQ ID NO:58) FcRHl forward, 5'- TCT TCA GAG ATG GCG AGG TCA-3' (SEQ ED NO:59) and reverse, 5'-TTT TGG GGT GTA CAT CAA CAT ACA AG-3' (SEQ ID NO:60); and FcRH forward, 5'-TGT TGC CCT GTT TCT TCC AAT ACA-3' (SEQ ED NO:61) and reverse, 5'-CAG AGT TGG CCG ACC TAC GC-3' (SEQ ID NO:62). Each amplification reaction underwent initial denaturation at 94° for 5 min followed by 35 cycles of denaturation at 94° for 30 s, annealing at 60° for 30 s, extension at 72° for 1 min, and final extension at 72° for 7 min. Amplified products were visualized in 1% agarose gels containing ethidium bromide and documented with the Bio-Rad Fluor-S hnager. The following human cell lines were used: REH and Nairn 16 pro-B cell lines
(Korsmeyer, S. J. et al. (1983) J. Clin. Invest. 71, 301-313); 697, 207, and OB5 pre-B cell lines (Findley, H. W. et al. (1982) Blood 60, 1305-1309; Martin, D. et al. (1991) J. Exp. Med. 173, 639-645); Ramos, Daudi, and Raji B cell lines (Pulvertaft, R. J. V. (1964) Lancet 1, 238-240; Klein, E. et al. (1968) Cancer Res. 28, 1300-1310; Klein, G. et al. (1975) Intervirology 5, 319-33431-33); THP-1 and U937 monocytoid cell lines, HL-60 promyelocytic and KG-1 myelocytic cell lines, Jurkat T cell line and the K562 erythroid cell line (American Type Culture Collection).
A consensus sequence was generated that corresponds to the GenBank-derived amino terminal sequences of the second Ig-like domains of FcR (FcγRI and FcγRII/iπ) and the third Ig-like domain of the polymeric Ig receptor:GEPIXLRCHSWΕ-DKXLXKVTYXQNGKAXKFFH (SEQ ID NO:63). A search of the National Center for Biotechnology Information protein database with this sequence identified two overlapping human genomic bacterial artificial chromosome (BAC) clones, AL135929 and AL356276, which are located at lq21.2-22. The second clone contained three putative Ig superfamily genes encoding complementary amino acid sequences that were designated FcRHl, FcRH2, and FcRH3. See Figure 1. The predicted amino acid sequences of these gene segments shared 23-57% identity with each other and 14-28%) identity with human FcγRI (CD64). Further analysis of the
FcRH locus led to the identification of two additional genes (FcRH4, and FcRH5) and one pseudogene (FcRH4ψ), immediately centromeric of FcRHl -3, two of which have recently been described as ERTA1 (FcRH4) and IRTA2 (FcRH5) (Hatzivassiliou, G. et al. (2001) Immunity 14, 277-289). To determine whether these genes are expressed by lymphocytes, the predicted amino acid sequences of their protein products were used to search the Lymphochip expressed sequence tag database with the TBLASTN algorithm (Alizadeh, A. A. et al. (2000) Nature (London) 403, 503-511). Two expressed sequence tags (AA505046 and AA282433) were identified that share complete identity over 23 amino acids in their translated ORFs with the N terminus of FcRHl . Lymphochip microarray data analysis indicated that these expressed sequence tags are expressed at relatively high levels in peripheral lymphoid tissues, including the lymph nodes, tonsils, resting peripheral B cells, and normal germinal center (GC) B cells. Among the different lymphoid malignancies, their expression proved to be highest in chronic lymphocytic leukemias, follicular lymphomas, and some diffuse large cell lymphomas of B lineage.
FcRHl, FcRH2, and FcRH3 cDNAs were isolated by RACE-PCR from a human lymph node cDNA library in both 5' and 3' directions. Full-length cDNAs of the coding regions for FcRHl, FcRH2, and FcRH3 were obtained by end-to-end PCR using unique primers generated from the cDNA sequences delineated for the 5' UT and 3'UT regions. Southern blot analysis of human genomic DNA digested with BamΗI, EcoRI, or HindUL using cDNA probes specific for the 3' UT regions of each cDNA revealed either one or two hybridizing fragments, suggesting that FcRHl, FcRH2, and FcRH3 are encoded by single genes. Analysis of full-length cDNA sequences indicated that FcRHl, FcRH2, and FcRH3 have ORFs of 1,287 bp, 1,524 bp, and 2,202 bp, respectively, and encode type I transmembrane proteins of 429 aa, 508 aa, and 734 aa, respectively. Based on predicted consensus signal peptide cleavage sites (Von Heijne, G. (1986) Nucleic Acid Res. 14, 4683-4690; Nielsen, H. (1997) Protein Εng. 10, 1-6), the relative core peptide molecular masses were estimated as 45,158 for FcRHl, 53,407 for FcRH2, and 78,849 for FcRH3. These type I transmembrane proteins possess 3-6 extracellular C2 (Williams, A. F. & Barclay, A. N. (1988) Annu. Rev. Immunol. 6, 381-405; Bork, P. et al. (1994) J. Mol. Biol. 242, 309-320; Vaughn, D. E. & Bjorkman, P. J. (1996) Neuron 16, 261-273) type Ig-like domains with 3-7 potential N-linked glycosylation sites, uncharged transmembrane segments, and relatively long cytoplasmic tails containing consensus motifs for ITIMs and/or ITAMs. See Fig. 2A.
Multiple alignment analysis of the translated cDNAs, using FcRH3 as the index sequence of comparison, indicates that FcRHl , FcRH2, and FcRH3 have highly conserved hydrophobic signal peptides and corresponding Ig-like extracellular domains (Fig. 2B). Their hydrophobic transmembrane (uncharged with the exception of FcRHl which includes an acidic domain) domains (Sonnhammer, E. L. L. et al. (1998) in A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences, eds. Glasgow, J, Littlejohn, T, Major, F, Lathrop, R, Sankoff, D. & Sensen, C. (Am. Assoc. for Artificial Intelligence, Menlo Park, CA), pp. 175-182) are also well conserved, but their cytoplasmic domains are not. FcRHl has a long cytoplasmic tail containing three potential ITAMs, the first and third of which fit the consensus sequence (E/D)-X-X-Y-X-X-(L/I)-X6.8-Y-X-X-(L/I) (SEQ ID NO:64, with six amino acid between the consensus sequences; SEQ ID NO:65, with seven amino acid residues between the consensus sequences; and SEQ ID NO: 66, with eight amino acid residues between the consensus sequences), whereas, the second has only one tyrosine residue. The shorter cytoplasmic domain of FcRH2 contains one potential ITAM and two ITIM consensus sequences (I/V/L/S)-X-Y-X-X-(L/V) (SEQ ID NO:67) separated by 22 amino acids. FcRH3 has the longest cytoplasmic tail. It contains one potential ITAM, one ITIM, and another potential ITAM that also has a single tyrosine residue.
An RNA blot analysis with gene-specific probes was performed on 16 human tissues, including six primary or secondary lymphoid tissues. RNA blots were analyzed with discriminating α32P-dCTP -labeled probes generated from the respective FcRH cDNAs. The following probes were used: (Top) a PCR-generated, 257-bp probe specific to the 3' UT region of FcRHl; (Middle) a PCR-generated, 290-bρ probe corresponding to the 3' UT region of FcRH2; and (Bottom) a 528-bp EcoRI-digested fragment of the 5' end of the FcRH3 cDNA corresponding to its 5' UT region, SI, S2, and EC1 domains. The relative mRNA abundance was indicated by β-actin probe. All three FcRH gene probes hybridized with transcripts in the secondary lymphoid organs, spleen and lymph node. An FcRHl -specific probe hybridized with spleen and lymph node transcripts of about 3.5 kb and about 6.0 kb. Additional hybridization bands of about 0.7 kb and about 1.5 kb were observed for heart, skeletal muscle, kidney, liver, and, in less abundance, placental tissue. Larger transcripts also were seen in skeletal muscle (about 6.0 kb) and in kidney and placenta (about 4.4 kb). An FcRH2-specific probe hybridized to about 3.0-kb, about 4.4-kb, and about 5.5-kb transcripts most abundantly in spleen and lymph node. A transcript of approximately 2.4-kb was notable in the kidney. An FcRH3 probe hybridized with about 3.5-kb, about 5.5-kb, and about 7.0-kb transcripts chiefly in spleen and lymph node. These also were seen, albeit in lesser abundance, in peripheral blood lymphocytes, thymus, and bone marrow samples. Additionally, a unique transcript of about 1.35 kb was evident in skeletal muscle. These results indicated expression of FcRHl, FcRH2, and FcRH3 in peripheral lymphoid organs, whereas tissue specific differences in alt +ernative splicing or polyadenylation were suggested by the differential expression of transcripts with variable size in nonlymphoid tissues. RTPCR analysis to date of non-lymphoid tissue skeletal muscle, however, does not reveal transcripts despite the Northern analysis results.
When FcRH expression was examined by RT-PCR analysis of cell lines representing different hematopoietic lineages, FcRHl, FcRH2, and FcRH3 expression + was found in every mature B cell line tested (Table 2). FcRH2 and FcRH3 expression was limited to the mature B cell lines and not seen in the other types of cells examined. In contrast, FcRHl expression was seen in pro-B, T, and myeloid cell lines, although not in an erythroid cell line.
Table 2. Expression of FcRH transcripts in human B cell lines
Cell Type Cell line FcRHl FcRH2 FcRH3
Pro-B REH +
Nairn 16 +
Pre-B 697 .
207 -
OB5 -
B Ramos Daudi + + +
Raji + + +
T Jurkat + - -
Monocytic THP-1 + - -
Myelomonocytic U937 + - -
Promyelocytic HL-60 + - -
Myelocytic KG-1 + - -
Erythroid K562 - - -
FcRHl, FcRH2, and FcRH3 expression in cell lines was determined by RT-PCR.
RT-PCR analysis of sorted populations of peripheral blood cells indicated that FcRHl, FcRH2, FcRH3, and FcRH5 are expressed at relatively high levels in CD 19+ B cells, whereas FcRH4 was expressed at only trace levels. FcRH3 expression was observed in CD3+ T cells whereas transcripts of FcRHl were barely detectable. FcRHl expression also was observed in circulating granulocytes.
To refine the analysis of FcRH expression in secondary lymphoid tissues, tonsillar lymphocyte subpopulations were isolated. The five discrete subpopulations of B lineage cells, which can be distinguished by their differential expression of cell surface IgD and CD38, represent different stages in B cell differentiation: follicular mantle (IgD+CD38), pre-GC (IgD+CD38+), GC (IgDCD38+), memory (IgDCD38), and mature plasma cells (CD382+) (Pascual, V. (1994) J. Exp. Med. 180: 329-339). RT- PCR analysis of FcRHl -5 expression in tonsillar B cell subpopulations was performed. Viable cells were magnetically sorted into CD19- non-B cells and CD19+ B cells. The latter were stained with anti-IgD and anti-CD38 mAbs, and the five subpopulations indicated (CD38- IgD-, CD38- IgD+, CD38+ IgD+, CD38+ IgD-, and CD382+) were sorted by flow cytometry. RT-PCR analysis of FcRH transcripts in non-B cells and the B cell subpopulations was also performed. After cDNA preparation, PCR amplification was performed on the equivalent template of approximately 10 k cells. Glyceraldehyde- 3-phosphate dehydrogenase (GADPH) was amplified as a positive control.
RT-PCR analysis indicated little or no expression of FcRH transcripts in the non-B lineage CD 19- cells, most of which are T cells. However, CD 19+ subpopulations displayed coordinate expression of FcRHl, FcRH2, and FcRH3 transcripts in follicular mantle, naϊve, GC, and memory B cell subpopulations, but yielded no evidence of FcRH transcripts in pre-GC B cells or plasma cells. In contrast, FcRH4 transcripts were restricted to the follicular mantle and memory B cells, whereas FcRH5 expression extended to mature plasma cells. The relationship between the five FcRHs was examined by comparing their full- length, extracellular, and individual Ig-like domain amino acid sequences. This analysis, which included a recently identified mouse FcRH ortholog (moFcRH) and members of the FcR family, used the CLUSTAL method algorithm (Higgins, D. G. & Shaφ, P. M. (1989) Comput. Appl. Biosci. 5, 151-153). Comparison of the full-length sequences of other FcRH family members with FcRH3 indicated 40-47% identity. By comparison, the degree of FcRH? homology with the moFcRH was found to be 35% and 21-24%) with FcR members residing on chromosome 1, FcγRI, FcγRII, FcγRUI, and FcεRI. A lower level of amino acid identity (14%) was observed for the chromosome 19 LRC member, FcαR. A slightly higher degree of extracellular homology was evident. Pairwise analysis of the individual Ig-like subunits indicated conservation in membrane-distal to membrane-proximal ordering of extracellular domain composition among family members. Although similar Ig domain subunits were shared among family members, the individual receptors were found to be composed of unique domain combinations. The extracellular domain configuration of the moFcRH most closely resembled that of FcRH2, with which it has 46% identity. The extended pairwise comparison of the FcRH family with known FcRs suggested the conservation of these Ig-like domains to some degree throughout the greater family. The resemblance is particularly evident in the FcRH3 membrane-distal domains that correspond to the three FcγRI domains and the two domains of FcγRII, FcγRIII, and the FcRγ-chain. This analysis suggests the ancestral occurrence of differential duplication and diversification of the individual Ig-like subunits in the respective FcRH family members. The data also indicate that the FcRHs are more similar to their FcR neighbors on chromosome 1 than to their FcR relative on chromosome 19.
The genomic sequence analysis of relevant chromosome lq21 BAC clones indicated that the entire FcRH locus spans 300 kb. The FcRH genes lie in the same transcriptional orientation toward the centomere. Exon-intron boundaries were characterized by sequence comparison of their respective cDNA clones and the AG/GT rale. The FcRHl gene consists of 11 exons and 10 introns spanning about 28 kb. The first exon, 5' UT/S1, encodes the 5' UT region, the ATG translation initiation codon, and the first half of a split signal peptide. S2, the second exon, is separated from 5' UT/S1 by a long intron of 12.9 kb and, like the neighboring FcRs, is
21 bp in length (van de Winkel, J. G. & Capel, P. J. (1993) Immunol. Today 14, 215- 221 ; Kulczycki, A, Jr. et al. (1990) Proc. Natl. Acad. Sci. USA 87, 2856-2860; Pang, J. et al. (1994) J. Immunol. 151, 6166-6174.). The extracellular region is encoded by three closely clustered exons, EC1-EC3, that code for the three Ig-like domains. The membrane-proximal, transmembrane, and the proximal portion of the cytoplasmic domain are encoded by a single sixth exon, TM. The cytoplasmic tail is encoded by five exons, CY1-CY5, and the CY5 also encodes the beginning of the 3' UT region.
FcRH2 contains 12 exons and 11 introns that span 30 kb. It also contains two exons that encode a split signal peptide, the first of which, 5'UT/S1, includes the 5' UT region, the ATG translation initiation codon, and first half of the signal peptide. The second exon, S2, is 21 bp in length. Exons 3-6 encode the four extracellular domains, EC1-EC4. The seventh exon encodes the membrane-proximal, transmembrane, and the proximal portion of the cytoplasmic domain. The FcRH2 cytoplasmic tail is encoded by five exons, CY1-CY5, the last exon of which includes the termination of the ORF and beginning of the 3' UT region.
The FcRH3 gene consists of 16 exons and 15 introns that span about 24 kb. Unlike FcRHl and FcRH2, its 5' UT region is encoded by two exons, 5' UT1 and a second, 5T T2/S1, that also encodes the ATG translation initiation codon and the beginning of the split signal peptide. The third exon, S2, is also 21 bp in length. Extracellular domains encoded by six exons, EC1-EC6, are followed by exon 10 that encodes the membrane-proximal, transmembrane, and the proximal portion of the cytoplasmic domain. The cytoplasmic tail is encoded by five exons, CY1-CY5; the last contains the beginning of the 3' UT region.
EXAMPLE 2 Identification of HuFcRHό FcRH6 is located in the midst of the classical FcRs at lq21-23. Its genomic structure indicates, like the classical FcRs and FcRHl -5, a split hydrophobic signal peptide encoded by two exons the second of which is 21bp. FcRH6 was characterized using the methods described in Example 1. A composite analysis of Ig-like domains for relatedness with the other huFcRHs was performed. See Figure xxx. Sequence analysis of huFcRH6 indicates its type I transmembrane form contains a consensus motif for a single ITAM, or a single or two ITIM's. Initial RT-PCR analysis of huFcRHό in human tissues and cell lines (as described in Example 1) reveals transcript expression in normal tonsil and lymph nodes. In cell lines, expression of huFcRHό was identified in myeloid cell lines THP-1 (monocytic), U937 (myelomonocytic), and KG-1 (myelocytic). Limited expression if any was identified in the 207 pre-B cell line and the Daudi B cell line.
EXAMPLE 3 Generation of Transfectants and Antibodies Recombinant constracts for transfection and stable expression of huFcRHl-5 have been generated. The constracts have been ligated into a CMV driven mammalian expression vector with and without green fluorescent protein (GFP) fusion at the carboxyl terminus. Surface expression of huFcRHl and huFcRH3 was detected for both GFP and non-GFP forms by staining with antibody supernatant. The antibody supernatant was derived from hybridomas generated by mice immunized with recombinant extracellular protein of the respective FcRH. The constracts for huFcRH2, 4, and 5 have been detected by green fluorescence as well as surface expression for FcRH4.
Monoclonal antibodies have been generated, including, for example, an antibody that binds FcRHl . The preliminary analysis of FACS staining for FcRHl expression with monoclonal antibody 1-5 A3 labeled with a FITC conjugate (mouse anti human FcRHl) in peripheral blood from normal volunteers indicates virtually all CD19+ B cells have huFcRHl expression, as do CD14+ monocytes and CD13+ granulocytes. CD3+ T cells have limited to no expression of FcRHl. Staining of B-CLL samples from two different patient peripheral blood samples indicates that virtually all CD5+/CD19+ B-CLL cells are positive for the FcRHl 1-5 A3 antigen. By western blot analysis of recombinant protein for FcRHl-5 extracellular regions 1-5A3 appears specific for FcRHl. 1-5A3 also stains B cell lines Daudi and Raji.
EXAMPLE 4
Identification of MoFcRH 1-3 A family of three mouse Fc Receptor Homologs (MoFCRHs) were identified and cloned. Amino acid sequences from the membrane proximal Ig-like domains of huFcRHl-5 were used to identify putative mouse FcRH orthologs in the NCBI or Celera genomic, EST, and protein databases using the protein BLAST (BLASTP) and the translated nucleotide BLAST (TBLASTN) algorithms, respectively. The location of moFcR family is split between chromosomes 1 and 3 in regions syntenic with human chromosome lq21-23. See Figure 4. The mo FcRH are located on mouse Ch3. Approximate positions were determined from Genbank, Celera, and Mouse Genome Informatics databasesContigs of ESTs were generated to determine the putative cDNA sequences.
Genomic organization was determined by comparing cDNA clones generated from RACE PCR with GenBank and Celera genomic sequences. DNAStar software was used for analysis of exon-intron boundaries which were characterized by sequence comparison and the AG/GT rule. All three genes contain a split signal sequence with a 21bp S2 exon (exon 2) which is found in all FcR and huFcRH genes on human chromosone 1.
A comparison of tyrosine based motifs in FcRH cytoplasmic tails indicated homology with the huFcRH family. See Figure 5. An analysis of sequence homology conservation is further shown in Figures 6 and 7.
Expression of the moFcRHs in tissue and cell lines was also characterized as described in Example 1. Briefly, RT-PCR was performed on mouse tissues and cell lines with gene specific primers. Viable tissue was placed in TRIzol reagent for RNA extraction. After cDNA preparation PCT amplification was performed on equivalent template amounts. Actin was amplified as a positive control. McFcRH3 appears to have preferential expression in cells of B lineage. The results are shown in Tables 3-4. Table 3: Tissue Distribution of moFcRH Expression
Figure imgf000055_0001
Table 4. Expression of moFcRH transcripts in cell '. ines
Cell Type Cell line FcRHl FcRH2 FcRH3
Pro-B SCID7 + +/- +
Raw8.1 + + -
Pre-B 70Z/3 + + +
BC76 - + +
18-81 + + + hum. B WEHI-231 + + +
WEHI-279 + + +
B A20 + + +
X16C8.5 + + +
T EL4 + +/- -/+
NKT NKT + +/- -
NKT 2C12 + +/- -
Myeloid WEHI-3 + - -
Lymphoid YAC-1 + + -
Fibroblast 3T3 + +/- -
Expression in cell lines was determined by RT-PCR.
The mouse FcReceptor Homologs include secreted or type I transmembrane isolfrms that have unique cytoplasmic tails with potential activation and inhibition motifs. Their chromosomal location, Ig domain homology, and genomic organization indicate the mouse FcReceptor Homologs are orthologs of the huFcRH that have evolved a significant level of diversity. moFcRHl, moFcRH2, and moFcRH3 are predicted to encode secreted or type I transmembrane proteins based on their amino acid sequences. moFcRHl has two secreted isoforms both of which have extracellular (EC) regions of four Ig-like domains with five potential sites for N-linked glycosylation. One isoform is a fusion protein with a type B scavenger receptor domain containing 8 cysteines. moFcRH2 has secreted and type I isoforms containing two Ig- like domains with five N-linked glycosylation sites. The type I isoform has an uncharged transmembrane region which the secreted isoform lacks. Both isoforms contain the cytoplasmic portion which is long in the transmembrane form and contains five tyrosines including a consensus sequence for one potential immunoreceptor tyrosine-based activating motif . moFcRH3 contains five Ig-like domains with six potential sites of N-linked glycosylation. Its transmembrane domain is also uncharged and the cytoplasmic region contains one potential ITAM and one potential immunoreceptor tyrosine-based inhibitory motif. The amino acid (aa) length of individual regions and full length (FL) isoforms, as well as approximate molecular weight (MW) in Daltons (Da), is indicated in the stractural diagram of Figure 8.
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incoφorated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

Claims

What is claimed is:
1. An isolated FcRH, comprising a cytoplasmic region with more than 107 or less than 104 amino acids, a transmembrance region, and an extracellular region.
2. The isolated FcRH of claim 1, wherein the extracellular region comprises less than four Ig domains.
3. The isolated FcRH of claim 2, wherein the cytoplamic region comprises less than 104 amino acids.
4. The isolated FcRH of claim 3, wherein the transmembrane region comprises an acidic amino acid.
5. The isolated FcRH of claim 4, wherein the acidic amino acid is glutamate.
6. The isolated FcRH of claim 2, wherein the cytoplasmic region comprises the amino acid sequence of SEQ ID NO: 1
7. The isolated FcRH of claim 2, wherein the extracellular region comprises the amino acid sequence of SEQ ED NO:21.
8. The isolated FcRH of claim 1 , comprising the amino acid sequence of SEQ ED NO:2.
9. The isolated FcRH of claim 1, wherein the receptor is expressed by myeloid cells.
10. The isolated FcRH of claim 9, wherein the receptor is expressed by T-cells.
11. A polypeptide comprising the amino acid sequence of SEQ ED NO: 1.
12. A polypeptide comprising the amino acid of SEQ ED NO: 1 with conservative amino acid substitutions.
13. A polypeptide comprising the amino acid sequence of SEQ ED NO:21
14. A polypeptide comprising the amino acid of SEQ ID NO:21 with conservative amino acid substitutions.
15. A polypeptide comprising the amino acid of SEQ ID NO:2.
16. A polypeptide comprising the amino acid of SEQ ED NO:2 with conservative amino acid substitutions.
17. The isolated FcRH of claim 1, wherein the cytoplasmic region comprises less than 99 amino acids and wherein the receptor further comprises an extracellular region with up to four Ig domain and up to five N-linked glycosylation sites.
18. The isolated FcRH of claim 17, wherein the cytoplasmic region comprises the amino acid sequence of SEQ ED NO:3.
19. The isolated FcRH of claim 17, wherein the extracellular region comprises the amino acid sequence of SEQ ID NO: 22.
20. The isolated FcRH of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
21. A polypeptide comprising the amino acid sequence of SEQ ID NO:3.
22. A polypeptide comprising the amino acid of SEQ ID NO:3 with conservative amino acid substitutions.
23. A polypeptide comprising the amino acid sequence of SEQ ED NO:22
24. A polypeptide comprising the amino acid of SEQ ED NO:22 with conservative amino acid substitutions.
25. A polypeptide comprising the amino acid of SEQ ED NO:4.
26. A polypeptide comprising the amino acid of SEQ ED NO:4 with conservative amino acid substitutions.
27. The isolated FcRH of claim 1, wherein the cytoplasmic region comprises more than 107 amino acids.
28. The isolated FcRH of claim 27, wherein the cytoplasmic region comprises the amino acid sequence of SEQ ID NO:5.
29. The isolated FcRH of claim 27, wherein the cytoplasmic region comprises the amino acid sequence of SEQ ID NO:23.
30. The isolated FcRH of claim 27, wherein the extracellular region comprises the amino acid sequence of SEQ ED NO: 24.
31. The isolated FcRH of claim 1, comprising the amino acid sequence of SEQ ED NO:6.
32. The isolated FcRH of claim 1, comprising the amino acid sequence of SEQ ID NO:25.
33. A polypeptide comprising the amino acid sequence of SEQ ED NO:5
34. A polypeptide comprising the amino acid of SEQ ED NO:5 with conservative amino acid substitutions.
35. A polypeptide comprising the amino acid sequence of SEQ ED NO: 24
36. A polypeptide comprising the amino acid of SEQ ED NO:24 with conservative amino acid substitutions.
37. A polypeptide comprising the amino acid sequence of SEQ ED NO:23
38. A polypeptide comprising the amino acid of SEQ ED NO:23 with conservative amino acid substitutions.
39. A polypeptide comprising the amino acid sequence of SEQ ED NO:6.
40. A polypeptide comprising the amino acid of SEQ ED NO: 6 with conservative amino acid substitutions.
41. A polypeptide comprising the amino acid sequence of SEQ ED NO:25.
42. A polypeptide comprising the amino acid of SEQ ED NO:25 with conservative amino acid substitutions.
43. The isolated FcRH of claim 1, wherein the cytoplasmic region comprises the amino acid sequence of SEQ ID NO:26.
44. The isolated FcRH of claim 1, wherein the extracellular region comprises the amino acid sequence of SEQ ID NO:27.
45. The isolated FcRH of claim 1, comprising the amino acid sequence of SEQ ID NO:28.
46. An isolated nucleic acid, comprising a nucleotide sequence that encodes the FcRH of claim 2.
47. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ DD NO:l.
48. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ DD NO:21.
49. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ID NO:2.
50. The nucleic acid of claim 46, comprising the nucleotide sequence of SEQ ID NO:7.
51. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ DD NO:7, or the complement of SEQ DD NO:7.
52. The nucleic acid of claim 46, comprising the nucleotide sequence of SEQ DD NO:13.
53. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 13 or the complement of SEQ
ID NO:13.
54. The nucleic acid of claim 46, comprising the nucleotide sequence of SEQ DD NO:8.
55. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ DD NO:8, or the complement of SEQ DD NO:8.
56. A single stranded nucleic acid that hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ DD NO:7, SEQ DD NO:13 or SEQ DD NO:8.
57. An isolated nucleic acid, comprising a nucleotide sequence that encodes the FcRH of claim 17.
58. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:3.
59. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:22.
60. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:4.
61. The nucleic acid of claim 57, comprising the nucleotide sequence of SEQ DD NO:9.
62. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ DD NO:9, or the complement of SEQ DD NO:9.
63. The nucleic acid of claim 57, comprising the nucleotide sequence of SEQ DD NO:14.
64. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 14, or the complement of SEQ ID NO: 14.
65. The nucleic acid of claim 57, comprising the nucleotide sequence of SEQ ED NO:10.
66. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ DD NO: 10, or the complement of SEQ ID NO: 10.
67. A single stranded nucleic acid that hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ DD NO:9, SEQ ED NO: 14, or SEQ ED NO:10.
68. An isolated nucleic acid, comprising a nucleotide sequence that encodes the FcRH of claim 27.
69. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ DD NO:5.
70. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ DD NO:23.
71. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:24.
72. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:6.
73. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ DD NO:25.
74. The nucleic acid of claim 68, comprising the nucleotide sequence of SEQ ED NO:ll.
75. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ DD NO: 11 , or the complement of SEQ ID NO:ll.
76. The nucleic acid of claim 68, comprising the nucleotide sequence of SEQ ED NO:16.
77. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 16, or the complement of SEQ ID NO:16.
78. The nucleic acid of claim 68, comprising the nucleotide sequence of SEQ ED NO:15.
79. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 15, or the complement of SEQ ID NO:15.
80. The nucleic acid of claim 68, comprising the nucleotide sequence of SEQ ED NO:12.
81. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 12, or the complement of SEQ ID NO: 12.
82. The nucleic acid of claim 68, comprising the nucleotide sequence of SEQ ED NO:17.
83. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 11 , or the complement of SEQ ED NO: 17.
84. A single stranded nucleic acid that hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ DD NO:ll, SEQ DD NO:15, SEQ DD NO: 16, or SEQ DD NO: 12.
85. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:26.
86. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ ED NO:27.
87. An isolated nucleic acid, comprising a nucleotide sequence that encodes SEQ DD NO:28.
88. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 18, or the complement of SEQ ID NO: 18.
89. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ DD NO: 19, or the complement of SEQ ID NO:19.
90. An isolated nucleic acid comprising a sequence that hybridizes under highly stringent conditions to a hybridization probe, wherein the hybridization probe comprises the nucleotide sequence of SEQ ED NO: 20, or the complement of SEQ ID NO:20.
91. A single stranded nucleic acid that hybridizes under stringent conditions to a nucleic acid having the sequence of SEQ ED NO: 18, SEQ ED NO: 19, or SEQ ED NO:20.
92. An expression vector comprising the nucleic acid of claim 46 operably linked to an expression control sequence.
93. An isolated cell comprising the vector of claim 92.
94. A method of making a FcRH, comprising culturing the cell of claim 93 under conditions permitting expression of the FcRH.
95. An expression vector comprising the nucleic acid of claim 57 operably linked to an expression control sequence.
96. An isolated cell comprising the vector of claim 95.
97. A method of making a FcRH, comprising culturing the cell of claim 96 under conditions permitting expression of the FcRH.
98. An expression vector comprising the nucleic acid of claim 56 operably linked to an expression control sequence.
99. An isolated cell comprising the vector of claim 98.
100. A method of making a FcRH, comprising culturing the cell of claim 99 under conditions permitting expression of the FcRH.
101. An expression vector comprising the nucleic acid of claim 57 operably linked to an expression control sequence.
102. An isolated cell comprising the vector of claim 101.
103. A method of making a FcRH, comprising culturing the cell of claim 102 under conditions permitting expression of the FcRH.
104. An expression vector comprising the nucleic acid of claim 67 operably linked to an expression control sequence.
105. An isolated cell comprising the vector of claim 104.
106. A method of making a FcRH, comprising culturing the cell of claim 105 under conditions permitting expression of the FcRH.
107. An expression vector comprising the nucleic acid of claim 68 operably linked to an expression control sequence.
108. An isolated cell comprising the vector of claim 107.
109. A method of making a FcRH, comprising culturing the cell of claim 108 under conditions permitting expression of the FcRH.
110. An expression vector comprising the nucleic acid of claim 91 operably linked to an expression control sequence.
111. An isolated cell comprising the vector of claim 110.
112. A method of making a FcRH, comprising culturing the cell of claim 111 under conditions permitting expression of the FcRH.
113. A purified antibody or immunonologic fragment thereof, wherein the antibody or fragment thereof selectively binds to the FcRH of claim 1.
114. A purified antibody or immunonologic fragment thereof, wherein the antibody or fragment thereof selectively binds to the FcRH of claim 2.
115. A purified antibody or immunonologic fragment thereof, wherein the antibody or fragment thereof selectively binds to the FcRH of claim 17.
116. A purified antibody or immunonologic fragment thereof, wherein the antibody or fragment thereof selectively binds to the FcRH of claim 27.
117. The antibody or fragment of claim 113, wherein the antibody or fragment is a monoclonal antibody or fragment thereof.
118. The antibody or fragment of claim 113, wherein the antibody or fragment thereof is a humanized antibody, a fully human antibody, or a fragment thereof.
119. The antibody or fragment of claim 113, wherein the antibody or fragment thereof is a single chain antibody or fragment thereof.
120. The antibody or fragment of claim 113, wherein the antibody or fragment thereof is labeled.
121. The antibody or fragment of claim 113, wherein the label is a radiolabel.
122. The antibody or fragment of claim 113, wherein the antibody or fragment is conjugated or fused with a toxin.
123. A purified antibody that selectively binds to the FcRH of claim 6, but not to the FcRH of claim 18, 28, or 43.
124. A purified antibody that selectively binds to the FcRH of claim 18, but not to the FcRH of claim 6, 28, or 43.
125. A purified antibody that selectively binds to the FcRH of claim 28, but not to the FcRH of claim 6, 18, or 43.
126. The purified antibody of claim 125, wherein the antibody does not bind to the FcRH of claim 29.
127. A purified antibody that selectively binds to the FcRH of claim 29, but not to the FcRH of claim 6, 18, or 43.
128. The purified antibody of claim 127, wherein the antibody does not bind to the FcRH of claim 28.
129. A purified antibody that selectively binds to the FcRH of claim 43 , but not to the FcRH of claim 6, 18, or 28.
130. A purified antibody that selectively binds to the FcRH of claim 7, but not to the FcRH of claim 19, 30, or 44.
131. A purified antibody that selectively binds to the FcRH of claim 19, but not to the FcRH of claim 7, 30, or 44.
132. A purified antibody that selectively binds to the FcRH of claim 30, but not to the FcRH of claim 7, 19, or 44.
133. A purified antibody that selectively binds to the FcRH of claim 44, but not to the FcRH of claim 7, 19, or 30.
134. A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
(a) contacting a biological sample of the subject with the antibody of claim 113 under conditions that allow the antibody to bind to an FcRH in the biological sample;
(b) detecting the amount or pattern of binding by the antibody, changes in the amount or pattern of binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage in the subject.
135. The method of claim 134, wherein the malignancy of hematopoietic cell lineage is a malignancy of B cell lineage.
136. The method of claim 134, wherein the malignancy of hematopoietic cell lineage is a malignancy of T cell lineage.
137. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 1.
138. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:21.
139. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:2.
140. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:3.
141. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:22.
142. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:4.
143. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 5.
144. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:23.
145. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 24.
146. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:6.
147. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:25.
148. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:26.
149. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 27.
150. The method of claim 134, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:28.
151. A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
(a) contacting the nucleic acid of claim 56 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with an FcRH in the biological sample; (b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage in the subject.
152. The method of claim 151, wherein the malignancy of hematopoietic cell lineage is a malignancy of B cell lineage.
153. The method of claim 151, wherein the malignancy of hematopoietic cell lineage is a malignancy of T cell lineage.
154. A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
(a) contacting the nucleic acid of claim 67 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage.
155. The method of claim 154, wherein the malignancy of hematopoietic cell lineage is a malignancy of B cell lineage.
156. The method of claim 154, wherein the malignancy of hematopoietic cell lineage is a malignancy of T cell lineage.
157. A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
(a) contacting the nucleic acid of claim 84 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage.
158. The method of claim 157, wherein the malignancy of hematopoietic cell lineage is a malignancy of B cell lineage.
159. The method of claim 157, wherein the malignancy of hematopoietic cell lineage is a malignancy of T cell lineage.
160. A method of diagnosing a malignancy of hematopoietic cell lineage in a subject, comprising:
(a) contacting the nucleic acid of claim 91 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating a malignancy of hematopoietic cell lineage.
161. The method of claim 160, wherein the malignancy of hematopoietic cell lineage is a malignancy of B cell lineage.
162. The method of claim 160, wherein the malignancy of hematopoietic cell lineage is a malignancy of T cell lineage.
163. A method of treating a malignancy of hematopoietic cell lineage in a subject, comprising contacting the subject's malignant cells with a therapeutically effective amount of the antibody of claim 113.
164. The method of claim 163, wherein the malignancy of hematopoietic cell lineage is a malignancy of B cell lineage.
165. The method of claim 163, wherein the malignancy of hematopoietic cell lineage is a malignancy of T cell lineage.
166. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 1.
167. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:21.
168. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:2.
169. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:3.
170. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:22.
171. The method of claim 163, wherem the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:4.
172. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 5.
173. The method of claim 163, wherem the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:23.
174. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:24.
175. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO: 6.
176. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ DD NO:25.
177. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO: 26.
178. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:27.
179. The method of claim 163, wherein the antibody selectively binds an FcRH having the amino acid sequence of SEQ ED NO:28.
180. A method of treating a malignancy of hematopoietic cell lineage in a subject, comprising contacting the subject's malignant cells with a therapeutically effective amount of the nucleic acid of claim 56.
181. A method of treating a malignancy of hematopoietic cell lineage in a subj ect, comprising contacting the subject's malignant cells with a therapeutically effective amount of the nucleic acid of claim 67.
182. A method of treating a malignancy of hematopoietic cell lineage in a subject, comprising contacting the subject's malignant cells with a therapeutically effective amount of the nucleic acid of claim 84.
183. A method of treating a malignancy of hematopoietic cell lineage in a subject, comprising contacting the subject's malignant cells with a therapeutically effective amount of the nucleic acid of claim 91.
184. A method of diagnosing an autoimmune disease in a subject, comprising:
(a) contacting a biological sample of the subject with the antibody of claim 113 under conditions that allow the antibody to bind to FcRH in the biological sample;
(b) detecting the amount or pattern of binding by the antibody, changes in the amount or pattern of binding as compared to binding in a control sample indicating an autoimmune disease in the subject.
185. A method of diagnosing an autoimmune disease in a subject, comprising:
(a) contacting the nucleic acid of claim 56 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating an autoimmune disease.
186. A method of diagnosing an autoimmune disease in a subject, comprising:
(a) contacting the nucleic acid of claim 67 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating an autoimmune disease.
187. A method of diagnosing an autoimmune disease in a subject, comprising:
(a) contacting the nucleic acid of claim 84 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating an autoimmune disease.
188. A method of diagnosing an autoimmune disease in a subject, comprising:
(a) contacting the nucleic acid of claim 91 with a biological sample of the subject under conditions that allow the nucleic acid to hybridize with the biological sample;
(b) detecting the amount or pattern of binding by the nucleic acid, changes in the amount or pattern of binding as compared to binding in a control sample indicating an autoimmune disease.
189. A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the antibody of claim 113, one or more FcRH expressing cells of the subject.
190. A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the nucleic acid of claim 56, FcRH expressing cells of the subject.
191. A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the nucleic acid of claim 67, FcRH expressing cells of the subject.
192. A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the nucleic acid of claim 84, FcRH expressing cells of the subject.
193. A method of treating an autoimmune disease in a subject, comprising contacting, with a therapeutically effective amount of the nucleic acid of claim 91, FcRH expressing cells of the subject.
194. A method of modulating a humoral immune response in a subject, comprising administering to the subject the isolated FcRH of claim 1.
195. A method of modulating a humoral immune response in a subject, comprising administering to the subject the antibody of claim 113.
196. A method of modulating a humoral immune response in a subject, comprising administering to the subject the nucleic acid of claim 56.
197. A method of modulating a humoral immune response in a subject, comprising administering to the subject the nucleic acid of claim 67.
198. A method of modulating a humoral immune response in a subject, comprising administering to the subject the nucleic acid of claim 84.
199. A method of modulating a humoral immune response in a subject, comprising administering to the subject the nucleic acid of claim 91.
200. An isolated mouse FcRH isoform of FcRHl, wherein the isoform lacks a cytoplasmic region.
201. A polypeptide comprising the amino acid sequence of SEQ ED NO: 70.
202. A polypeptide comprising the amino acid of SEQ DD NO:70 with conservative amino acid substitutions.
203. An isolated mouse FcRH isoform of FcRH2, wherem the FcRH lacks a transmembrane region.
204. A polypeptide comprising the amino acid sequence of SEQ ED NO:73.
205. A polypeptide comprising the amino acid of SEQ ED NO:73 with conservative amino acid substitutions.
206. A polypeptide comprising the amino acid of SEQ ED NO: .77.
207. A polypeptide comprising the amino acid of SEQ DD NO:77 with conservative amino acid substitutions.
208. A polypeptide comprising the amino acid sequence of SEQ DD NO:78.
209. A polypeptide comprising the amino acid sequence of SEQ DD NO:78 with conservative amino acid substitutions.
210. A nucleic acid encoding the isolated mouse FcRH isofomi of claim 200.
211. A nucleic acid encoding the isolated mouse FcRH isoform of claim 203.
212. A nucleic acid encoding the polypeptide of claim 201.
213. A nucleic acid encoding the polypeptide of claim 202.
214. A nucleic acid encoding the polypeptide of claim 204.
215. A nucleic acid encoding the polypeptide of claim 205.
216. A nucleic acid encoding the polypeptide of claim 206.
217. A nucleic acid encoding the polypeptide of claim 207.
218. A nucleic acid encoding the polypeptide of claim 208.
219. A nucleic acid encoding the polypeptide of claim 209.
PCT/US2003/009600 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof WO2003089624A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003245239A AU2003245239A1 (en) 2002-03-25 2003-03-25 FC receptor homolog, reagents, and uses thereof
CA002480404A CA2480404A1 (en) 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof
EP03738876A EP1490085A2 (en) 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof
US10/508,374 US7317087B2 (en) 2002-03-25 2003-03-25 Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
JP2003586337A JP2005521429A (en) 2002-03-25 2003-03-25 Fc receptor homologues, reagents and uses thereof
US11/835,226 US8648171B2 (en) 2002-03-25 2007-08-07 Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36766702P 2002-03-25 2002-03-25
US60/367,667 2002-03-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10508374 A-371-Of-International 2003-03-25
US11/835,226 Division US8648171B2 (en) 2002-03-25 2007-08-07 Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof

Publications (2)

Publication Number Publication Date
WO2003089624A2 true WO2003089624A2 (en) 2003-10-30
WO2003089624A3 WO2003089624A3 (en) 2004-02-05

Family

ID=29250463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009600 WO2003089624A2 (en) 2002-03-25 2003-03-25 Fc receptor homolog, reagents, and uses thereof

Country Status (6)

Country Link
US (2) US7317087B2 (en)
EP (1) EP1490085A2 (en)
JP (1) JP2005521429A (en)
AU (1) AU2003245239A1 (en)
CA (1) CA2480404A1 (en)
WO (1) WO2003089624A2 (en)

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030955A1 (en) * 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Protein expressed in nk cell
WO2005063299A2 (en) * 2003-12-24 2005-07-14 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
EP1740210A2 (en) * 2004-03-29 2007-01-10 Medarex, Inc. Irta-5 antibodies and their uses
EP1809670A2 (en) * 2004-09-29 2007-07-25 Medarex, Inc. Irta-4 antibodies and their uses
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP2260858A2 (en) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP2286844A2 (en) 2004-06-01 2011-02-23 Genentech, Inc. Antibody-drug conjugates and methods
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
WO2011056983A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8648171B2 (en) 2002-03-25 2014-02-11 The Uab Research Foundation Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014159981A2 (en) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
EP3088004A1 (en) 2004-09-23 2016-11-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2017059289A1 (en) 2015-10-02 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
US9657106B2 (en) 2003-03-03 2017-05-23 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3235820A1 (en) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
WO2020049286A1 (en) 2018-09-03 2020-03-12 Femtogenix Limited Polycyclic amides as cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020157491A1 (en) 2019-01-29 2020-08-06 Femtogenix Limited G-a crosslinking cytotoxic agents
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2022023735A1 (en) 2020-07-28 2022-02-03 Femtogenix Limited Cytotoxic agents
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11401348B2 (en) 2009-09-02 2022-08-02 Xencor, Inc. Heterodimeric Fc variants
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates
US11820830B2 (en) 2004-07-20 2023-11-21 Xencor, Inc. Optimized Fc variants
US11932685B2 (en) 2007-10-31 2024-03-19 Xencor, Inc. Fc variants with altered binding to FcRn
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037048A2 (en) * 2004-09-27 2006-04-06 The Uab Research Foundation Fc RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF
US20100285007A1 (en) * 2007-09-14 2010-11-11 The Uab Research Foundation Differential diagnosis of b-cell chronic lymphocytic leukemia
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
WO2014096368A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
JP6527466B2 (en) 2012-12-21 2019-06-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Asymmetric pyrrolobenzodiazepine dimers for use in the treatment of proliferative and autoimmune diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038490A2 (en) * 1999-11-29 2001-05-31 The Trustees Of Columbia University In The City Of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US20030078396A1 (en) * 2000-03-01 2003-04-24 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1112395B (en) * 1979-03-23 1986-01-13 Giovanetti Fiorello JUNCTION DEVICE SUITABLE FOR JOINING TWO PIECES OR PANELS IN A REMOVABLE WAY
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3681787D1 (en) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst EXPRESSION OF FOREIGN GENETIC MATERIAL IN EPITHELIC CELLS.
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0732397A3 (en) 1988-02-05 1996-10-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
JP3082204B2 (en) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ Recombinant retrovirus with an amphotropic and ecotropic host range
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
RU2139092C1 (en) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Use of antibody fragment in therapy
AU2404001A (en) * 2000-01-06 2001-07-16 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
EP1201681A1 (en) * 2000-10-30 2002-05-02 Millennium Pharmaceuticals, Inc. "Fail" molecules and uses thereof
WO2005063299A2 (en) 2003-12-24 2005-07-14 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
CA2480404A1 (en) 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
WO2006037048A2 (en) 2004-09-27 2006-04-06 The Uab Research Foundation Fc RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038490A2 (en) * 1999-11-29 2001-05-31 The Trustees Of Columbia University In The City Of New York ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA
US20030078396A1 (en) * 2000-03-01 2003-04-24 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARLSSON ET AL.: 'Expression of GcgammaRIII defines distinct subpopulations of fetalk liver B cell and myeloid precursors' EUR J. IMMUNOL. vol. 25, no. 8, August 1995, pages 2308 - 2317, XP002971666 *
DAVIS R.S. ET AL.: 'Fc receptor homologs: Newest members of a remarkably diverse Fc receptor gene family' IMMUNOLOGICAL REVIEWS vol. 190, 2002, pages 123 - 136, XP002971663 *
DAVIS R.S. ET AL.: 'Identification of a family of Fc receptor homologs with preferential B cell expression' PROC. NATL. ACAD. SCI. USA vol. 98, no. 17, 14 August 2001, pages 9772 - 9777, XP002971662 *
KANT A.M. ET AL.: 'Heterogeneity in the expression of FcgammaRIII in morphologically mature granulocytes from patients with chronic myeloid leukemia' LEUKEMIA RESEARCH vol. 21, no. 3, March 1997, pages 225 - 234, XP002971664 *
MORTON H.C. ET AL.: 'Alternatively spliced forms of the human myeloid Fcalpha receptor (CD89) in neutrophils' IMMUNOGENETICS vol. 43, no. 4, 1996, pages 246 - 247, XP002971665 *
MORTON H.C. ET AL.: 'Structure and function of human IgA Fc receptors (FcalphaR)' CRITICAL REVIEWS IN IMMUNOLOGY vol. 16, no. 4, 1996, pages 423 - 440, XP002066873 *

Cited By (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8734791B2 (en) 2002-03-01 2014-05-27 Xencor, Inc. Optimized fc variants and methods for their generation
US8648171B2 (en) 2002-03-25 2014-02-11 The Uab Research Foundation Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof
US8809503B2 (en) 2002-09-27 2014-08-19 Xencor, Inc. Optimized Fc variants and methods for their generation
US10183999B2 (en) 2002-09-27 2019-01-22 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093359B2 (en) 2002-09-27 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US9193798B2 (en) 2002-09-27 2015-11-24 Xencor, Inc. Optimized Fc variants and methods for their generation
US8858937B2 (en) 2002-09-27 2014-10-14 Xencor, Inc. Optimized Fc variants and methods for their generation
US10184000B2 (en) 2002-09-27 2019-01-22 Xencor, Inc. Optimized Fc variants and methods for their generation
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US9353187B2 (en) 2002-09-27 2016-05-31 Xencor, Inc. Optimized FC variants and methods for their generation
US8383109B2 (en) 2002-09-27 2013-02-26 Xencor, Inc. Optimized Fc variants and methods for their generation
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US10113001B2 (en) 2003-03-03 2018-10-30 Xencor, Inc. Fc variants with increased affinity for FcyRIIc
US9663582B2 (en) 2003-03-03 2017-05-30 Xencor, Inc. Optimized Fc variants
US10584176B2 (en) 2003-03-03 2020-03-10 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9657106B2 (en) 2003-03-03 2017-05-23 Xencor, Inc. Optimized Fc variants
US8735545B2 (en) 2003-03-03 2014-05-27 Xencor, Inc. Fc variants having increased affinity for fcyrllc
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8946386B2 (en) 2003-09-29 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Proteins expressed in NK cells
WO2005030955A1 (en) * 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Protein expressed in nk cell
EP2478912A1 (en) 2003-11-06 2012-07-25 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP3858387A1 (en) 2003-11-06 2021-08-04 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
EP2260858A2 (en) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
EP2486933A1 (en) 2003-11-06 2012-08-15 Seattle Genetics, Inc. Monomethylvaline compounds conjugated with antibodies
EP2489364A1 (en) 2003-11-06 2012-08-22 Seattle Genetics, Inc. Monomethylvaline compounds onjugated to antibodies
EP3120861A1 (en) 2003-11-06 2017-01-25 Seattle Genetics, Inc. Intermediate for conjugate preparation comprising auristatin derivatives and a linker
WO2005063299A3 (en) * 2003-12-24 2006-06-01 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005063299A2 (en) * 2003-12-24 2005-07-14 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2004308972B2 (en) * 2003-12-24 2009-05-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2004308972C1 (en) * 2003-12-24 2009-11-26 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1740210A2 (en) * 2004-03-29 2007-01-10 Medarex, Inc. Irta-5 antibodies and their uses
EP1740210A4 (en) * 2004-03-29 2009-03-25 Medarex Inc Irta-5 antibodies and their uses
EP2286844A2 (en) 2004-06-01 2011-02-23 Genentech, Inc. Antibody-drug conjugates and methods
US11820830B2 (en) 2004-07-20 2023-11-21 Xencor, Inc. Optimized Fc variants
EP3088004A1 (en) 2004-09-23 2016-11-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP1809670A2 (en) * 2004-09-29 2007-07-25 Medarex, Inc. Irta-4 antibodies and their uses
EP1809670A4 (en) * 2004-09-29 2009-04-01 Medarex Inc Irta-4 antibodies and their uses
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8338574B2 (en) 2004-11-12 2012-12-25 Xencor, Inc. FC variants with altered binding to FCRN
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US10336818B2 (en) 2004-11-12 2019-07-02 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US11198739B2 (en) 2004-11-12 2021-12-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8324351B2 (en) 2004-11-12 2012-12-04 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9803023B2 (en) 2004-11-12 2017-10-31 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9574006B2 (en) 2005-10-06 2017-02-21 Xencor, Inc. Optimized anti-CD30 antibodies
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US11618788B2 (en) 2006-08-14 2023-04-04 Xencor, Inc. Optimized antibodies that target CD19
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US10626182B2 (en) 2006-08-14 2020-04-21 Xencor, Inc. Optimized antibodies that target CD19
US9803020B2 (en) 2006-08-14 2017-10-31 Xencor, Inc. Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US9040042B2 (en) 2006-09-18 2015-05-26 Xencor, Inc. Optimized antibodies that target HM1.24
WO2008103905A3 (en) * 2007-02-23 2008-12-31 Us Gov Health & Human Serv Antibodies that specifically bind irta and methods of use
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
US11932685B2 (en) 2007-10-31 2024-03-19 Xencor, Inc. Fc variants with altered binding to FcRn
US11401348B2 (en) 2009-09-02 2022-08-02 Xencor, Inc. Heterodimeric Fc variants
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
WO2011056983A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US10335497B2 (en) 2012-10-12 2019-07-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
US12121590B2 (en) 2012-10-12 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10646584B2 (en) 2012-10-12 2020-05-12 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11779650B2 (en) 2012-10-12 2023-10-10 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11771775B2 (en) 2012-10-12 2023-10-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9889207B2 (en) 2012-10-12 2018-02-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10780181B2 (en) 2012-10-12 2020-09-22 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11701430B2 (en) 2012-10-12 2023-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10994023B2 (en) 2012-10-12 2021-05-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10722594B2 (en) 2012-10-12 2020-07-28 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US11690918B2 (en) 2012-10-12 2023-07-04 Medimmune Limited Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10799596B2 (en) 2012-10-12 2020-10-13 Adc Therapeutics S.A. Pyrrolobenzodiazepine-antibody conjugates
EP2839860A1 (en) 2012-10-12 2015-02-25 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2014159981A2 (en) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
WO2016040856A2 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3235820A1 (en) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates
WO2017059289A1 (en) 2015-10-02 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP4273551A2 (en) 2016-03-25 2023-11-08 F. Hoffmann-La Roche AG Multiplexed total antibody and antibody-conjugated drug quantification assay
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11813335B2 (en) 2017-02-08 2023-11-14 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11938192B2 (en) 2017-06-14 2024-03-26 Medimmune Limited Dosage regimes for the administration of an anti-CD19 ADC
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
WO2020049286A1 (en) 2018-09-03 2020-03-12 Femtogenix Limited Polycyclic amides as cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
WO2020157491A1 (en) 2019-01-29 2020-08-06 Femtogenix Limited G-a crosslinking cytotoxic agents
WO2022023735A1 (en) 2020-07-28 2022-02-03 Femtogenix Limited Cytotoxic agents
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Also Published As

Publication number Publication date
CA2480404A1 (en) 2003-10-30
US8648171B2 (en) 2014-02-11
US7317087B2 (en) 2008-01-08
US20080089887A1 (en) 2008-04-17
US20050240006A1 (en) 2005-10-27
EP1490085A2 (en) 2004-12-29
AU2003245239A1 (en) 2003-11-03
WO2003089624A3 (en) 2004-02-05
JP2005521429A (en) 2005-07-21

Similar Documents

Publication Publication Date Title
US8648171B2 (en) Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof
KR0169728B1 (en) Intercellular adhesion molecule-2
US5594120A (en) Integrin alpha subunit
US20020151485A1 (en) Methods and compositions for modulating fertility
EP2902414A1 (en) Antibodies directed against glycoprotein VI and uses thereof
US7589074B2 (en) Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20030211517A1 (en) Gp354 nucleic acids and polypeptides
US20070065875A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
JPH09508781A (en) Lymphocyte activation antigen HB15: a type of immunoglobulin superfamily
JPH11225774A (en) Member of immunoglobulin gene superfamily, pigr-1
WO2001046260A2 (en) Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
Hale et al. Recognition of CD52 allelic gene products by CAMPATH‐1H antibodies
WO1997021450A1 (en) Ox-2 costimulatory molecule
AU2002325333A1 (en) NTB-A, a surface molecule involved in natural killer cells activity
CA2411101C (en) A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
JP2008509655A (en) UNC5H2 splice variant
US20030165495A1 (en) Nucleic acids and polypeptides
EP1207905B1 (en) Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
CA2472111A1 (en) Human mast cell-expressed membrane proteins
CA2412610A1 (en) Gp286 nucleic acids and polypeptides
US5700658A (en) ICAM-4 materials and methods
ES2352497T3 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASE THROUGH THE USE OF MODULATING AGENTS OF CADHERINA-11.
US20020146767A1 (en) Human EMR1-like G protein-coupled receptor
AU2001272982A1 (en) GP286 nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003245239

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003586337

Country of ref document: JP

Ref document number: 2480404

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003738876

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003738876

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10508374

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003738876

Country of ref document: EP